Journal articles on the topic 'Employee ownership – United States'
To see the other types of publications on this topic, follow the link: Employee ownership – United States.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Employee ownership – United States.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Mygind, Niels. "Drivers and barriers for employee ownership – why is the United States in a positive circle while Denmark is not?" Journal of Participation and Employee Ownership 4, no. 1 (June 7, 2021): 42–62. http://dx.doi.org/10.1108/jpeo-06-2020-0015.
Full textAbstract:
PurposeDrivers and barriers for employee ownership vary between countries because of differences in Politics, Institutions and the Economy (PIE). By analyzing this variation, the purpose of this study is to answer why employee ownership has developed fast in the United States and not in Denmark.Design/methodology/approachThe drivers and barriers for employee ownership are identified from the scientific literature, and the main societal dynamics are identified through the PIE model covering the dynamics between politics, institutional change and the economy. Politics focuses on different social groups influencing the development of institutions driving or hindering employee ownership in the economy.FindingsUnited States has followed a self-enforcing circle with broad political support of “shared capitalism,” including the employee stock ownership plan (ESOP) type of employee ownership. In Denmark, the labor movement rejected worker cooperatives as a main strategy and focused on building up the welfare state. Center-right parties favored employee stocks, but the institutional framework never overcame the barriers for employee ownership.Originality/valueThis is the first study to perform an analysis of politics, institutional change and economic development to explain drivers and barriers for employee ownership and to make a comparison between the development of employee ownership in the United States and Denmark.
2
Sari, Brimanti. "Employee Financial Participation Plan Implementation in the United States and the Netherlands: Lessons for Indonesia." Corporate and Trade Law Review 1, no. 1 (December 23, 2020): 1–22. http://dx.doi.org/10.21632/ctlr.1.1.1-22.
Full textAbstract:
Employees have a major role in the sustainability of an organization. Employee satisfaction and business accomplishment are equally significant for the company’s sustainability. One of the strategies companies undertake to create a harmonious workplace and stimulate productivity is by giving recognition, awards and/or compensation to their employees. In recent years, equity-based compensation through employee financial participation plans has been becoming more popular. There are several tailor-made participation schemes which may vary among jurisdictions. There include Stock Grants, Direct Employee Stock Purchase Plans, Phantom Stock, Stock Appreciation Rights (SARs) and Employee Stock Ownership Plans (ESOP). Consequently, the employees could be the beneficiary owner of the shares or be actual shareholders in the company. When employees own shares, they will be treated as shareholders. Depending on the restrictions laid out in the employee financial participation plan. This means that employees could be involved in corporate governance in the company.
3
Conte, Michael A. "Economic Research and Public Policy toward Employee Ownership in the United States." Journal of Economic Issues 28, no. 2 (June 1994): 427–37. http://dx.doi.org/10.1080/00213624.1994.11505557.
Full text
4
Setzler, Bradley, and Felix Tintelnot. "The Effects of Foreign Multinationals on Workers and Firms in the United States." Quarterly Journal of Economics 136, no. 3 (May 3, 2021): 1943–91. http://dx.doi.org/10.1093/qje/qjab015.
Full textAbstract:
Abstract Governments go to great lengths to attract foreign multinationals because they are thought to raise the wages paid to their employees (direct effects) and to improve outcomes at local domestic firms (indirect effects). We construct the first U.S. employer-employee data set with foreign ownership information from tax records to measure these direct and indirect effects. We find the average direct effect of a foreign multinational firm on its U.S. workers is a 7% increase in wages. This premium is larger for higher-skilled workers and for the employees of firms from high GDP per capita countries. We find evidence that it is membership in a multinational production network—instead of foreignness—that generates the foreign-firm premium. We leverage the past spatial clustering of foreign-owned firms by country of ownership to identify the indirect effects. An expansion in the foreign-multinational share of commuting-zone employment substantially increases the employment, value added, and—for higher-earning workers—wages at local domestic-owned firms. Per job created by a foreign multinational, our estimates suggest annual gains of US$13,400 to the aggregate wages of local incumbents, two-thirds of which are from indirect effects. Our estimates suggest that—via mega-deals for subsidies from local governments—foreign multinationals are able to extract a sizable fraction of the local surplus they generate.
5
Blasi, Joseph, Douglas Kruse, James Sesil, and Maya Kroumova. "An assessment of employee ownership in the United States with implications for the EU." International Journal of Human Resource Management 14, no. 6 (September 2003): 893–919. http://dx.doi.org/10.1080/0958519032000106137.
Full text
6
Nelson, David E., Jeffrey J. Sacks, and David G. Addiss. "Smoking Policies of Licensed Child Day-Care Centers in the United States." Pediatrics 91, no. 2 (February 1, 1993): 460–63. http://dx.doi.org/10.1542/peds.91.2.460.
Full textAbstract:
The authors analyzed data from a national survey of 2003 directors of licensed child day-care centers to determine employee smoking policies, measure compliance with state and local employee smoking regulations for child day-care centers and state clean indoor air laws, and to estimate the extent of exposure to environmental tobacco smoke in these settings. Forty states regulated employee smoking in child day-care centers, but only three states required day-care centers to be smoke-free indoors. More than 99% of licensed child day-care centers had employee smoking policies that complied with the appropriate state or local smoking regulations. Nearly 55% of centers were smoke-free indoors and outdoors, and 26% were smoke-free indoors only. The best predictors of more stringent employee smoking policies were location in the West or South, smaller size, independent ownership, or having written smoking policies. Despite the presence of strong smoking policies at the majority of licensed child day-care centers, more than 752000 children in the United States are at risk for environmental tobacco smoke exposure in these settings. Health care professionals and parents should insist that child day-care centers be smoke-free indoors and, preferably, smoke-free indoors and outdoors.
7
Kim, Minseo, and Terry A. Beehr. "Self-Efficacy and Psychological Ownership Mediate the Effects of Empowering Leadership on Both Good and Bad Employee Behaviors." Journal of Leadership & Organizational Studies 24, no. 4 (April 7, 2017): 466–78. http://dx.doi.org/10.1177/1548051817702078.
Full textAbstract:
This study examined the potential effects of empowering leadership on followers’ in-role performance and deviant behaviors via self-efficacy and psychological ownership over a 3-week period in a sample of 299 full-time employees working in the United States. Results from structural equation modeling demonstrated that empowering leadership was positively related to both self-efficacy and psychological ownership, which in turn were both negatively related to deviant behaviors. Alternative model comparisons and bootstrapping both confirmed the mediation effects of self-efficacy and psychological ownership. However, only one of the two mediators, self-efficacy, was positively related to followers’ in-role performance. Together, these findings highlighted the important roles of self-efficacy and psychological ownership explaining why empowering leadership may result in followers’ behaviors.
8
Blasi, Joseph R., and Douglas L. Kruse. "The Political Economy of Employee Ownership in the United States: From Economic Democracy to Industrial Democracy?" International Review of Sociology 16, no. 1 (March 2006): 127–47. http://dx.doi.org/10.1080/03906700500485762.
Full text
9
Kaya, Halil D., and Nancy L. Lumpkin-Sowers. "Composition of blockholders in publicly traded firms." Corporate Ownership and Control 14, no. 2 (2017): 88–97. http://dx.doi.org/10.22495/cocv14i2art9.
Full textAbstract:
The outside blockholder has become an important agent in the corporate governance literature in the United States. Understanding how his monitoring role changes as economic circumstances deteriorate is rarely considered. In this study, we examine whether the number of certain types of blockholders, as well as their ownership concentrations, will increase during recessions. By categorizing blockholders by type: affiliated, outside, employee (through Employee Stock Ownership Plans), non-officer director, and officer director, we are able to track how blockholder composition changed within firms when the economy moved from expansion in 1999 to recession in 2001. Using nonparametric tests, we show that the number of outside blockholders and their ownership stake go up during the recessionary period examined. This suggests a more important monitoring role for the outside blockholder when the economy worsens. Though we do not find a statistically significant change overall in the average number of blockholders or the total percentage of shares held across the firms in our sample for the other blockholder types when the economy moves from expansion to recession, we do see noteworthy changes in the behavior of the affiliated and ESOP blockholder at specific ownership concentration levels when the economy shifts.
10
Hogan, Karen M., and Gerard T. Olson. "Governance and corporate control in the United States." Corporate Law and Governance Review 3, no. 2 (2021): 41–52. http://dx.doi.org/10.22495/clgrv3i2p4.
Full textAbstract:
This paper provides an overview of business entities in the United States. We analyze current trends in the ownership structures of U.S. firms, diversity and inclusion, mergers and acquisitions, minority shareholder rights protections, and review the literature related to corporate ownership and financial performance. With the shift in the U.S. from defined benefit pension plans to defined contribution plans and a desire for increased corporate governance, we observe a significant increase in the financial assets under management by large institutional investors. It is believed these large institutional investors can have a significant impact on the governance, decision-making, and performance of the U.S. publicly traded firms. We observe an increasing trend in foreign indirect investment in the U.S. from countries in Europe, Asia and the Pacific Rim, North and South America, the Middle East, and Africa. Additionally, increased compensation of publicly traded firms’ top executives is shown, which has resulted in an increased disparity between the compensation of top management teams and the firms’ hourly employees. Lastly, we expect the suggested bias against women and other minorities, as evidenced here, will be lessened in the future and should result in improved financial performance for firms
11
Ma, Te, Mahdi Aghaabbasi, Mujahid Ali, Rosilawati Zainol, Amin Jan, Abdeliazim Mustafa Mohamed, and Abdullah Mohamed. "Nonlinear Relationships between Vehicle Ownership and Household Travel Characteristics and Built Environment Attributes in the US Using the XGBT Algorithm." Sustainability 14, no. 6 (March 14, 2022): 3395. http://dx.doi.org/10.3390/su14063395.
Full textAbstract:
In the United States, several studies have looked at the association between automobile ownership and sociodemographic factors and built environment qualities, but few have looked at household travel characteristics. Their interactions and nonlinear linkages are frequently overlooked in existing studies. Utilizing the 2017 US National Household Travel Survey, the authors employed an extreme gradient boosting tree model to evaluate the nonlinear and interaction impacts of household travel characteristics and built environment factors on vehicle ownership in three states of the United States (California, Missouri, and Kansas) that are different in population size. To develop these models, three main XGBT parameters, including the number of trees, maximal depth, and minimum rows, were optimized using a grid search technique. In California, the predictability of vehicle ownership was driven by household travel characteristics (cumulative importance: 0.62). Predictions for vehicle ownership in Missouri and Kansas were dominantly influenced by sociodemographic factors (cumulative importance: 0.53 and 0.55, respectively). In all states, the authors found that the number of drivers in a household plays a vital role in the vehicle ownership decisions of households. Regarding the built environment attributes, deficiencies in cycling infrastructure were the most prominent attribute in predicting household vehicle ownership in California. This variable, however, has threshold connections with vehicle ownership, but the magnitude of these relationships is small. The outcomes imply that improving the condition of cycling infrastructure will help reduce the number of vehicles. In addition, incentives that encourage the households’ drivers not to buy new vehicles are helpful. The outcomes of this study might aid policymakers in developing policies that encourage sustainable vehicle ownership in the United States.
12
Mygrant, Mark S. "Keeping profits at home: A study of firm ownership and the geographical concentration of capital gains in the United States." Local Economy: The Journal of the Local Economy Policy Unit 35, no. 5 (June 3, 2020): 460–81. http://dx.doi.org/10.1177/0269094220927337.
Full textAbstract:
Approximately 39% of American wealth exists in the form of private ownership in firms. Surprisingly, the existing economic geography literature offers us little insight into where the owners of this vast wealth reside relative to the firms they own, nor of the potentially important economic implications of this unknown geographical proximity. This comparative case study utilizes a unique dataset to examine three mid-size American manufacturing firms with varied ownership structures. It finds that the employee-owned firm and family-owned firm concentrate firm-created wealth in local communities to a greater degree than the publicly traded firm. Building on this empirical evidence, the paper then uses both Endogenous and Keynesian growth theory to argue that this concentration can feasibly lead to local economic growth through subsequent local reinvestment of that wealth. This theoretical insight is important because it offers a new perspective on the multifaceted debate concerning which firms should receive incentives from local policymakers. Results imply that public policy requiring local ownership as a condition of incentives is in the long-term economic interest of local residents. This pilot work contributes to the existing academic literature by justifying subsequent studies on the economic geography of firm ownership and by establishing methodological precedent on the subject.
13
Bagja Rahma Putra. "Pengaruh Penerapan Employee Stock Option Plan (Esop) Terhadap Kinerja Perusahaan Dan Nilai Perusahaan Dengan Profitabilitas Sebagai Variabel Moderasi." Jurnal Bisnisman : Riset Bisnis dan Manajemen 4, no. 2 (September 28, 2022): 10–20. http://dx.doi.org/10.52005/bisnisman.v4i2.104.
Full textAbstract:
The Employee Stock Option Plan (ESOP) is a share ownership program implemented in the company, this ESOP program aims to serve as a reward for employees who have good performance where the criteria for receiving this ESOP have been determined by each company, United States of America. is the first country to implement this ESOP program, with various benefits for employees through this share ownership program, the ESOP itself began to be implemented by certain companies in Indonesia regulated by PSAK No. 53 which according to PSAK, payments by companies to employees are not only in the form of monetary value but can be in the form of share options that can be used as opportunities by companies that aim to increase employee motivation, performance and loyalty to the company which will ultimately have an impact on the value of the company itself. In Indonesia, company management has its own rules in the process of implementing the ESOP, one of which is to use the vesting method, this method contains that every employee who receives the option right is prohibited from selling his shares unless requested by the company or an employee has retired. From the results of statistical tests whether the variable current ratio (X1) and Price Book Value (X2) have an effect if the company carries out the ESOP program but the results show that if a company implements the ESOP, it has no effect on the current ratio or price book value, but the existence of ESOP can strengthen these ratios. Variable current ratio, price book value and return on assets have an effect on the ESOP only 33%.
14
Ulcickas Yood, Marianne, Susan Jick, Catherine Vasilakis-Scaramozza, Bonnie M. K. Donato, Ioannis Tomazos, Gilbert L'Italien, Nicholas Sicignano, and Brian L. Feldman. "The Value of Population Based Data to Study Rare Diseases: An Example Using the Department of Defense Healthcare System." Blood 132, Supplement 1 (November 29, 2018): 5829. http://dx.doi.org/10.1182/blood-2018-99-113497.
Full textAbstract:
Abstract Background: For patients suffering from rare diseases, accurate and early diagnosis is critical and often lifesaving, whereas misdiagnosis can be fatal. While patient registries are useful and necessary, they may not provide reliable patient population denominators or sufficient longitudinal clinical follow-up. Access to complete and integrated patient records necessary to capture full clinical history can be challenging. Commonly, there is a lack of centralized and continuous care in the health care systems of many countries, including the United States (US). It is also challenging to identify a sufficient number of cases to provide robust results because of the rare nature of these diseases. We describe a healthcare system that can identify patients for research purposes, who have rare diseases, by accessing de-identified electronic clinical details. We used Paroxysmal Nocturnal Hemoglobinuria (PNH) as an example of a rare disease for this abstract. Methods: The Department of Defense (DOD) healthcare system is a US-based, longitudinal electronic health record (EHR) and claims database with health information on approximately 10 million active beneficiaries across the country. We evaluated the feasibility to conduct studies of rare diseases in the DOD healthcare system by assessing the capability to identify patients with PNH and to describe their course of disease and treatment. We used ICD 9/10 diagnosis codes, NDC and HCPCS codes, laboratory data and PNH treatment codes to identify patients with a clinical course consistent with PNH. Patients were classified as definite/likely, probable/possible or unlikely PNH based on the available clinical evidence and then findings were validated against review of patient records by a clinical expert. Individuals classified as unlikely PNH were excluded from the study. The clinical information on these patients will be used to understand the course of PNH in patients with and without treatments and to describe their treatment adherence and disease activity over time. Results: We identified 244 people with a diagnosis or treatment code that was indicative of PNH during years 2007-2017; 71% of the patients had electronic records that covered 10 or more years starting as early as 2003 and extending as far as 2017. From these 244 patients, we identified 73 patients with a definite/likely or probable/ possible PNH diagnosis. An ICD-10 code for PNH or a prescription for eculizumab (PNH treatment) were required, but not sufficient to confirm the presence of PNH. There is no ICD-9 code for PNH. Cases had no other indication for eculizumab use and had to have appropriate symptoms, comorbidities or lab results to be considered a case. Patients with only 1 code for PNH and no treatment were assumed to have unconfirmed disease and were excluded. 27 cases, including those with no eculizumab and a random sample of likely cases, were reviewed to validate the PNH diagnoses in collaboration with DOD treating physicians. Conclusion: The DOD healthcare system is a valuable and cost effective resource for the study of rare diseases in a timely manner. We have demonstrated the ability to identify a validated series of PNH cases that will provide important clinical insights for identifying and treating new PNH cases. This healthcare system provides long patient follow-up, demographics similar to the US population, and access to records in an integrated inpatient, outpatient and ER system that encompasses all patient care. Disclaimer Statement: Research data were derived from an approved Naval Medical Center, Portsmouth, VA IRB protocol (NMCP.2017.0080). The views expressed in this abstract are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense or the United States Government. Copyright Notice: CAPT Brian Feldman is a military service member. This work was prepared as part of his official duties. Title 17 U.S.C. 105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. 101 defines a United States Government work as a work prepared by a military service member or employee of the United States Government as part of that person's official duties. Disclosures Ulcickas Yood: Alexion Pharmaceuticals, Inc.: Other: Employee of EpiSource, LLC, which was contracted by Alexion Pharmaceuticals, Inc. EpiSource had the final decision on content. . Jick:Alexion Pharmaceuticals, Inc.: Other: Employee of the Boston Collaborative Drug Surveillance Program, which was contracted and paid by Alexion Pharmaceuticals, Inc. to work on a study of PNH using DOD data. . Vasilakis-Scaramozza:Alexion Pharmaceuticals, Inc.: Other: Employee of the Boston Collaborative Drug Surveillance Program, which was contracted and paid by Alexion Pharmaceuticals, Inc. to work on a study of PNH using DOD data.. Donato:Alexion Pharmaceuticals Inc: Employment, Equity Ownership. Tomazos:Alexion Pharmaceuticals, Inc.: Employment, Equity Ownership. L'Italien:Alexion Pharmaceuticals, Inc.: Equity Ownership, Other: Former employee and current stockholder of Alexion Pharmaceuticals, Inc. . Sicignano:Alexion Pharmaceuticals, Inc.: Other: Employee of Health ResearchTx, which has a business relationship with Alexion Pharmaceuticals, Inc.. Feldman:Alexion Pharmaceuticals, Inc.: Other: Employee, Department of Navy, United States Government..
15
Cetin, Karynsa, Leah J. McGrath, Robert Overman, Diane Reams, Anjali Sharma, M. Alan Brookhart, Ivy Altomare, and Jeffrey S. Wasser. "Treatment Patterns Among Adults with Newly Diagnosed Primary Immune Thrombocytopenia in the United States." Blood 132, Supplement 1 (November 29, 2018): 497. http://dx.doi.org/10.1182/blood-2018-99-117252.
Full textAbstract:
Abstract Introduction: Immune thrombocytopenia (ITP) is a rare platelet disorder that can lead to an increased tendency to bleed. Recommended first-line therapies include corticosteroids, intravenous immunoglobulin (IVIg) and intravenous (IV) anti-D. An estimated two-thirds of adult patients with ITP will develop persistent or chronic disease (ITP lasting 3-12 months or >12 months, respectively). Several evidence-based options for second-line treatment exist, but no randomized trials have directly compared one therapy to another. Patterns of treatment in routine clinical practice therefore vary. There is a paucity of data on current real-world treatment dynamics in ITP, and such data could help identify gaps in care and inform future studies of real-world comparative effectiveness and safety. We described the types of treatments administered following an ITP diagnosis, as well as the subsequent occurrence of bleeding and requirement for rescue therapy among adults being managed in routine practice in the United States (US). Methods: We used electronic health record data from hematology clinics across the US (Flatiron Health, Inc.) linked to MarketScan® employer-based and Medicare Supplemental administrative health insurance claims databases (Truven Health Analytics, Inc.). We included patients aged 18 years or older with a new ITP diagnosis from January 1, 2011 through June 30, 2016, continuous enrollment in MarketScan prior to diagnosis, and no previous diagnosis of a secondary cause of thrombocytopenia. The cumulative incidence of each ITP treatment after diagnosis was estimated using competing risk models to account for deaths occurring before initiation. Estimates were provided specifically for 90 days and 1 year following diagnosis to describe treatment uptake in the newly diagnosed and persistent phases, respectively. The incidence of bleeding events and rescue therapy was quantified after the start of the more prevalent second-line therapies: rituximab, splenectomy, and thrombopoietin receptor agonists (TPO RAs) - eltrombopag and romiplostim. Rescue therapies (those that rapidly increase platelet counts in the setting of severe thrombocytopenia or active bleeding) included IV anti-D, IVIg, IV steroids, and platelet transfusions. Results: Among the cohort of 447 adults diagnosed with primary ITP, 47% were male, 61% were white, 32% were 65 years or older, and the median lowest platelet count in the 60 days prior to diagnosis was 85x109/L (IQR: 39, 125). Use of each ITP therapy by 90 days and 12 months post-diagnosis are provided in the Table. Oral corticosteroids were the most commonly used; the cumulative incidence of initiation was 41% by 90 days and 50% by 1 year following ITP diagnosis. IV steroids and rituximab were the next most frequently used medications (16% and 11% at 90 days; and 26% and 16% by 1 year, respectively). The cumulative incidence of the TPO RAs, eltrombopag and romiplostim, by 90 days was 3% and 7%, respectively, and by 1 year was 5% and 9%, respectively. Splenectomy was relatively rare (<4% by 1 year) as was use of all other non-rescue ITP medications (≤1% by 1 year). At 180 days post-ITP treatment initiation, rituximab initiators (N = 84) had a slightly lower incidence of bleeding overall (12% [6, 20]) than the other treatment groups (17% [6, 33] among 31 eltrombopag initiators; 19% [9, 31] among 49 romiplostim initiators; and 19% [6, 38] among 21 splenectomized patients). However, rituximab initiators had the highest cumulative incidence of rescue therapy use (48% [36, 58] compared with 29% [14, 46] for eltrombopag, 26% [14, 39] for romiplostim, and 19% [6, 39] for splenectomized patients). Subsequent oral steroid use was less frequent among TPO RA initiators than rituximab initiators or patients who underwent splenectomy. Conclusions: In this descriptive study of patients with primary ITP receiving care in the US, oral steroids were the most commonly used medication after diagnosis, reflecting their continued role as a frontline therapy. By 1 year after diagnosis, approximately 15% received rituximab, nearly 10% received romiplostim, and 5% received eltrombopag. Splenectomy was less common. Among the medical treatments, although bleeding risk overall appeared lowest in rituximab patients, oral steroid and rescue therapy use were lowest among the patients who initiated TPO RAs. Table. Table. Disclosures Cetin: Amgen Inc: Employment, Equity Ownership. Sharma:Amgen: Employment, Equity Ownership. Brookhart:Amgen Inc: Consultancy, Research Funding; NoviSci: Equity Ownership; Union Chimique Belge: Consultancy; GlaxoSmithKline: Consultancy; Merck: Consultancy; Genentech: Consultancy; TargetPharma: Consultancy; RxAnte: Consultancy; AstraZeneca: Research Funding. Altomare:Genentech: Consultancy; Ipsen: Other: Advisory Board Member; Amgen: Consultancy; Celgene: Other: Advisory Board Member; Novartis: Consultancy; Bayer: Consultancy; Incyte: Consultancy. Wasser:Amgen Inc: Consultancy; Novartis: Consultancy; Becton Dickinson: Equity Ownership; Abbott Labs: Equity Ownership; Biogen: Equity Ownership; Allergan: Equity Ownership; Eli Lilly: Equity Ownership; Incyte: Research Funding; Merck: Equity Ownership, Research Funding; Pfizer: Equity Ownership, Research Funding; Guardant: Research Funding.
16
Hoffman, Christy L. "The Experience of Teleworking with Dogs and Cats in the United States during COVID-19." Animals 11, no. 2 (January 21, 2021): 268. http://dx.doi.org/10.3390/ani11020268.
Full textAbstract:
In Spring of 2020, the novel coronavirus (SAR-CoV-2) prompted an unprecedented number of individuals across the United States to begin working from home. Prior research has identified both positive and negative impacts of teleworking on employee well-being, and this study built on that research to explore perceptions regarding how companion animals factor into the teleworking experience. Individuals who had experience working from home and from their employer’s office completed an online survey about those experiences. Participants reported spending more quality time with their companion animals and family members when they worked from home. Furthermore, when working from home, individuals with dogs were more likely than those without dogs to report they socialized with other people, got a healthy amount of physical activity, and took at least one 15-min walk during the workday. Some participants, particularly those in households containing both dogs and cats, indicated that their pets created distractions during the workday. Future studies can build on this research by investigating whether the findings persist once the novel coronavirus is no longer a threat, and by paying close attention to the characteristics of pets, owners, and household dynamics that may influence the effects of pet ownership on the teleworking experience.
17
Ulcickas Yood, Marianne, Susan Jick, Catherine Vasilakis-Scaramozza, Bonnie M. K. Donato, Ioannis Tomazos, Gilbert L'Italien, Nicholas Sicignano, and Brian L. Feldman. "Baseline Characteristics of Patients with Paroxysmal Nocturnal Hemoglobinuria Identified in the Department of Defense Database." Blood 132, Supplement 1 (November 29, 2018): 5830. http://dx.doi.org/10.1182/blood-2018-99-113478.
Full textAbstract:
Abstract Background: Rare diseases are often characterized by misdiagnosis resulting in delays in critical and potentially lifesaving treatment. Awareness of first signs and symptoms of rare diseases can provide clinical evidence for early and accurate diagnosis. Medical records are the primary source of clinical information from first signs and symptoms to key clinical disease related events, yet access to records can be difficult and time consuming. We conducted a study using a large electronic medical record (EMR) and claims database to identify and describe characteristics of Paroxysmal Nocturnal Hemoglobinuria (PNH) patients at the time of their PNH diagnosis. We present baseline findings of the PNH population identified in the Department of Defense (DOD) healthcare system, where all clinical details were readily available. The DOD healthcare system is a US-based, longitudinal EMR and claims database with health information on approximately 10 million active beneficiaries throughout the country. Methods: We identified all people in the DOD database from January 01, 2007 through May 31, 2017 who had an ICD-10-CM code for PNH or a NDC or HCPCS code for eculizumab, the drug used to treat PNH. There is no ICD-9-CM code for PNH. Cases had no other indication for eculizumab use and had to have appropriate symptoms, comorbidities or lab results to be considered a case. We reviewed the electronic record for each patient and classified each as definite/likely, probable/possible or unlikely PNH based on attributes of the available health data including codes for eculizumab, flow cytometry, lab results, hemoglobinuria, aplastic anemia, pancytopenia and other comorbidities. Our ruling was validated by medical record review by a clinical expert for all equivocal cases and a sample of definite/likely cases. Individuals classified as unlikely PNH were excluded. Patient characteristics at PNH diagnosis are presented using descriptive statistics. Results: We identified 73 PNH patients (55% female) after review of all available electronic data; 41 had a diagnosis of PNH and received eculizumab, 17 had a diagnosis of PNH only, and 15 received eculizumab only. From these, 61 patients were determined to have definite/likely PNH and 12 had probable/possible PNH. The use of eculizumab ranged from 0 to 378 (median=18) prescriptions, dependent in part on the amount of follow-up in the database. There were 19 patients (26%) who had prevalent PNH and 54 (74%) who were newly diagnosed with PNH during the study period. Among newly diagnosed patients, the median age at PNH diagnosis was 46 years (range 13 - 86). Most patients had codes for hemoglobinuria at or before the PNH diagnosis date (69%), and many had codes for aplastic anemia (46%), thrombocytopenia (56%), and pancytopenia (28%). At any time after the PNH diagnosis, 85% had unspecified anemia, 52% had aplastic anemia, 53% had thrombocytopenia, and 33% had pancytopenia codes in their records. See table. Conclusion: From a population of around 10 million actively enrolled patients, across a 10-year study period, we identified 73 patients with PNH. Data from these patients will be used to identify patterns of health encounters leading up to diagnosis and relevant outcomes following diagnosis. This information can be used to help diagnose other patients with this rare disease and to improve their medical outcomes. Disclaimer Statement: Research data were derived from an approved Naval Medical Center, Portsmouth, VA IRB protocol (NMCP.2017.0080). The views expressed in this abstract are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense or the United States Government. Copyright Notice: CAPT Brian Feldman is a military service member. This work was prepared as part of his official duties. Title 17 U.S.C. 105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. 101 defines a United States Government work as a work prepared by a military service member or employee of the United States Government as part of that person's official duties. Table. Table. Disclosures Ulcickas Yood: Alexion Pharmaceuticals, Inc.: Other: Employee of EpiSource, LLC, which was contracted by Alexion Pharmaceuticals, Inc. EpiSource had the final decision on content. . Jick:Alexion Pharmaceuticals, Inc.: Other: Employee of the Boston Collaborative Drug Surveillance Program, which was contracted and paid by Alexion Pharmaceuticals, Inc. to work on a study of PNH using DOD data. . Vasilakis-Scaramozza:Alexion Pharmaceuticals, Inc.: Other: Employee of the Boston Collaborative Drug Surveillance Program, which was contracted and paid by Alexion Pharmaceuticals, Inc. to work on a study of PNH using DOD data.. Donato:Alexion Pharmaceuticals Inc: Employment, Equity Ownership. Tomazos:Alexion Pharmaceuticals, Inc.: Employment, Equity Ownership. L'Italien:Alexion Pharmaceuticals, Inc.: Equity Ownership, Other: Former employee and current stockholder of Alexion Pharmaceuticals, Inc. . Sicignano:Alexion Pharmaceuticals, Inc.: Other: Employee of Health ResearchTx, which has a business relationship with Alexion Pharmaceuticals, Inc.. Feldman:Alexion Pharmaceuticals, Inc.: Other: Employee, Department of Navy, United States Government..
18
Abramowitz, Joelle. "New Insights on Self-Employment of Older Adults in the United States." Innovation in Aging 4, Supplement_1 (December 1, 2020): 460. http://dx.doi.org/10.1093/geroni/igaa057.1490.
Full textAbstract:
Abstract This work examines the nature of self-employment arrangements of older adults in the United States. Many people engage in self-employment - in the 2016 Health and Retirement Study (HRS), 20 percent of respondents working for pay reported being self-employed - yet there exists a dearth of data on these arrangements. This lack of data prevents consideration of important questions relevant to employment, inequality, and policy. Who works in different types of self-employment? What resources facilitate some individuals obtaining higher quality self-employment arrangements? To what extent does the income from different types of arrangements keep people out of poverty? Are different types of arrangements associated with individuals being happier and having more job satisfaction? This work leverages novel restricted-access data collected in the HRS in 2016 on the employer names and locations for individuals reporting self-employment along with respondent narratives on industry and type of work to classify self-employment reports into three entrepreneurial roles (own/run; manage; independent) across 14 different types of work. Using the breadth of information collected in the HRS and linkage to administrative records, this work then presents differences in characteristics, such as demographics, income, wealth, savings, health insurance coverage, home ownership, health status, and expectations of working longer, associated with different classifications of self-employment. Exploring these questions provides unique insights into the changing nature of work and the transition to retirement relevant to policy considerations across the health, insurance, and retirement income dimensions, among others.
19
Susaeta, Andres, and Janaki Alavalapati. "Forest Ownership, Management, and Water Production in Longleaf Pine Forests: A Stochastic Frontier Analysis." Forest Science 67, no. 2 (January 11, 2021): 145–55. http://dx.doi.org/10.1093/forsci/fxaa048.
Full textAbstract:
Abstract This study employed stochastic frontier analysis to determine the effects of forest ownership and management on the technical efficiency of water production from longleaf pine forests in the southern United States. Data at the forest-plot level were obtained from the Forest Inventory Analysis, climatic models, and water supply relationships. Results showed that the provision of water was inefficient and significantly different between public and private ownership. Longleaf pine forests under public ownership were modestly more efficient (2.2%–1.5%) in the production of water than private longleaf pine forests. Forest management had a negative impact on the efficiency in water production for privately and publicly owned longleaf pine forests. If 1 hectare of longleaf pine supplied on average 5,000 cubic meters of water per year, the production of water on public and private lands would be reduced to 4,960 and 4,800 cubic meters per year, respectively, with forest management. Efficiency in water supply was found to decline over time in both types of forest ownership.
20
Yu, Jingbo, Shreekant Parasuraman, Dilan Paranagama, Ahmad Naim, David Dubinski, Andrew Bai, and Ruben Mesa. "Impact of Myeloproliferative Neoplasms on Patients' Employment Status and Work Productivity in the United States: Results from the Living with MPN Patient Survey." Blood 128, no. 22 (December 2, 2016): 4256. http://dx.doi.org/10.1182/blood.v128.22.4256.4256.
Full textAbstract:
Abstract Background: Patients with myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), report high symptom burden that may compromise activities of daily living and quality of life. Results from the MPN Landmark survey suggest that for gainfully employed patients, disease symptoms may impact work productivity or career opportunities. The objective of this study was to assess the effects of MPNs on employment status, work productivity, and daily activities of patients in the United States. Methods: Adult patients (18-70 years) diagnosed with MF, PV, or ET participated in an online survey conducted between April and July 2016. The survey asked about diagnosis, disease-related history, MPN-related symptoms, functional status, changes in employment status since diagnosis due to MPNs, and work productivity (assessed using the Work Productivity and Activity Impairment Specific Health Problem Questionnaire, WPAI-SHP V2). Descriptive statistics were used to report MPN-related symptoms, employment changes, and WPAI scores for patients with MPNs who were employed at diagnosis and currently. Results: A total of 595 patients (MF, n=148; PV, n=284; ET, n=163) completed the survey, with 387 (65.0%) employed full- or part-time at diagnosis (MF, n=90; PV, n=178; ET, n=119). Among patients who were employed at diagnosis, mean (SD) age was 54.3 (10.5) years, 70.0% were female, and 47.8% had a bachelor's degree or higher. Mean (SD) duration of disease was 6.4 (6.6) years. After diagnosis, almost half of the patients (49.9%) experienced ≥1 change in employment resulting from their MPN, one-third (34.1%) had ≥2 different types of changes, and almost one-quarter (22.7%) had ≥3 different types of changes (Table). Almost one-third of patients (31.3%) reported 'leaving a job' due to their condition, which was also the most common employment change. The mean (SD) time from diagnosis to first job change due to MPN disease was 2.4 (5.2) years. Among those currently employed, the mean percentage of overall effects on work productivity due to MPNs were 29.3% for work impairment (MF, 28.4%; PV, 30.0%; ET, 28.6%), 25.7% for impairment while at work (presenteeism; MF, 22.1%; PV, 26.5%; ET, 26.4%), and 6.4% for work time missed (absenteeism; MF, 9.4%; PV, 6.6%; ET, 4.9%). The mean (SD) number of hours of work missed per week was 2.0 (4.9). The mean percentage of daily activity impairment was 31.6% (MF, 32.1%; PV, 32.0%; ET, 30.8%). The effects of MPNs on work productivity and daily activities are similar to those reported by patients with other significant chronic conditions such as rheumatoid arthritis (work time missed, 19.1%; impairment while working, 24.0%; activity impairment; 33.3%; Bansback N, et al. Rheumatology. 2012;51:375-84). Conclusion: MPNs have a substantial negative impact on patients' employment status and work productivity. Half of the employed patients with MPNs surveyed had a change in employment status (eg, leaving job, medical disability leave, early retirement) due to their disease. Moreover, currently employed patients reported a meaningful loss in work productivity due to their MPNs. Disclosures Yu: Incyte Corporation: Employment, Equity Ownership. Parasuraman:Incyte Corporation: Employment, Equity Ownership. Paranagama:Incyte Corporation: Employment, Equity Ownership. Naim:Incyte Corporation: Employment, Equity Ownership. Dubinski:Incyte Corporation: Employment, Equity Ownership. Bai:Incyte Corporation: Employment, Equity Ownership. Mesa:Novartis: Consultancy; Galena: Consultancy; Ariad: Consultancy; Incyte Corporation: Research Funding; Promedior: Research Funding; Gilead: Research Funding; Celgene: Research Funding; CTI: Research Funding.
21
Boccia, Ralph V., Brady Stein, Ruben A. Mesa, Ahmad B. Naim, Joseph A. Cordaro, Wei Peng, Hao Sun, Shreekant V. Parasuraman, and Alison Moliterno. "Burden of Phlebotomy in Patients with Polycythemia Vera in the United States: Baseline Data from the REVEAL Study." Blood 126, no. 23 (December 3, 2015): 5187. http://dx.doi.org/10.1182/blood.v126.23.5187.5187.
Full textAbstract:
Abstract Background: Phlebotomy to maintain hematocrit <45% is considered one of the cornerstones for the management of polycythemia vera (PV). However, phlebotomy procedures may be inconvenient for or poorly tolerated by some patients, and often result in iron deficiency, which may be associated with additional quality-of-life burden, such as fatigue, impaired cognitive function and restless leg syndrome. The REVEAL study (ClinicalTrials.gov, NCT02252159) is being conducted to describe contemporary demographics, burden of disease, clinical management, patient-reported outcomes, and healthcare resource utilization among patients with PV in the US. This early analysis describes the patient self-reported burden of phlebotomy at the time of enrollment. Methods: REVEAL is a multicenter, noninterventional, nonrandomized, prospective, observational study of adult patients with PV who are currently under the care of a US physician. REVEAL collects physician assessments and patient-reported outcomes during a 36-month observation period. Phlebotomy-related burden is being assessed with a new 21-item phlebotomy burden questionnaire (PBQ-21) at enrollment and every 90 days thereafter; it assesses patient-reported phlebotomy frequency, practice setting, time required for phlebotomy, inconvenience, and phlebotomy-related adverse effects. Phlebotomy-related effects and bother/inconvenience (if experienced within 24 hours after a phlebotomy procedure) are graded on a 4-point scale of 1 (not at all) to 4 (extremely). Analyses of these preliminary data were descriptive. Results: At the time of data cutoff, 865 patients were enrolled (total planned enrollment, n=2000). Median age was 67 (range, 22-95) years, 55.5% were male, and 89.5% were white. Median time from PV diagnosis to study enrollment was 53 months. Overall, 748 patients completed the PBQ-21 at enrollment and 400 (53.5%) had received a phlebotomy within 3 months prior to enrollment. Mean number of phlebotomies in the past 3 months was 2.2 (SD, 1.7). Phlebotomy was most commonly performed at a doctor's office during a regular medical visit (37.8%), at an infusion center or special cancer care center (26.8%), or at a hospital (18.3%). Patients who had phlebotomy procedures within 90 days before enrollment reported a mean total treatment time of 4.2 (SD, 4.7) hours per phlebotomy procedure; for employed patients, the mean amount of work time missed was 4.6 (SD, 15.6) hours per procedure. Fatigue, bruising, dehydration, and dizziness were among the most commonly reported adverse effects of phlebotomy (Table 1). Twenty percent of patients reported that phlebotomy procedures were moderately or extremely bothersome, inconvenient (18.3%), or painful or physically uncomfortable (16.3%). Furthermore, some patients (8.8%) reported that their family and friends were moderately or severely inconvenienced by phlebotomy procedures. Conclusion: The PBQ-21 collects important and relevant patient-reported information to systematically assess the impact of phlebotomy on patients and caregivers. From the early view of REVEAL enrollment data, a considerable proportion of patients reported fatigue, bruising, dehydration, and dizziness resulting from phlebotomy procedures. Furthermore, patients reported spending a considerable amount of time (4 hours on average) per phlebotomy procedure, which is a sizeable burden for patients who are employed. In addition, some patients reported that phlebotomy procedures may be inconvenient, painful or uncomfortable, and bothersome. REVEAL provides important information for providers to understand and address when to prescribe phlebotomy for patients with PV. Disclosures Boccia: Incyte Corporation: Honoraria. Stein:Incyte Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees. Mesa:Genentech: Research Funding; Promedior: Research Funding; NS Pharma: Research Funding; CTI Biopharma: Research Funding; Gilead: Research Funding; Incyte Corporation: Research Funding; Novartis Pharmaceuticals Corporation: Consultancy; Pfizer: Research Funding. Naim:Incyte Corporation: Employment, Equity Ownership. Cordaro:Incyte Corporation: Employment, Equity Ownership. Peng:Incyte Corporation: Employment, Equity Ownership. Sun:Incyte Corporation: Employment, Equity Ownership. Parasuraman:Incyte Corporation: Employment, Equity Ownership. Moliterno:Incyte Corporation: Membership on an entity's Board of Directors or advisory committees.
22
Brown, William S. "Socially Responsible Entrepreneurship as Innovative Human Resource Practice." Journal of Applied Behavioral Science 54, no. 2 (January 11, 2018): 171–86. http://dx.doi.org/10.1177/0021886317752146.
Full textAbstract:
This article examines how a single entrepreneur-owner of a heavy manufacturing firm in the United States has been influenced by the experience of the Mondragon cooperatives in Spain and the concept of servant leadership as articulated by Robert K. Greenleaf. The case that follows describes how this entrepreneur has attempted to not only sell his company to his employees at below market value but also to engage in a large scale training and development program so the employees may not only exercise ownership but also leadership and governance. His goal is to provide lifelong security and employment for the employees who made his company the success it is.
23
Vasigh, Bijan, and Clara Vydyanath Howard. "Evaluating airport and seaport privatization: a synthesis of the effects of the forms of ownership on performance." Journal of Transport Literature 6, no. 1 (March 2012): 08–36. http://dx.doi.org/10.1590/s2238-10312012000100002.
Full textAbstract:
Assessing the effects of ownership structure on efficiency has received considerable attention in the aviation management literature. Commercialization has been widely employed both in developing and developed countries as a means of increasing operational efficiency. Since airports and seaports are operationally similar, this paper examines the literature and methods used to assess the effects of privatization in both types of infrastructure. We observe that the impact of privatization on performance depends not only on the degree of privatization but on the competition in the market. Following a 4-level specification commonly employed in the seaport literature that captures degrees of privatization, we estimate a stochastic frontier model for airport efficiency as a function of ownership. We conclude that airport authorities in the United States are equally as efficient as fully privatized airports elsewhere, due to a high degree of competition and fiscal independence from the other governmental entities. Additionally, while privatization may be an effective mechanism of introducing corporatization into infrastructures that are characterized by poor competition and direct government control, the airport authority appears to achieve the benefits of privatization in operation without actual transfer of ownership.
24
Gutierrez-Li, Alejandro. "Self-Employment and Migration: Evidence from Mexico." AEA Papers and Proceedings 112 (May 1, 2022): 361–65. http://dx.doi.org/10.1257/pandp.20221112.
Full textAbstract:
Mexico has one of the highest self-employment rates in the OECD. I study the relationship between business ownership and migration from Mexico to the United States using longitudinal data from the Mexican Migration Project (MMP). I find that the self-employed have a substantially lower probability of moving north, either legally or illegally. Although running a business could allow a person to finance a costly trip to the US, it also raises the opportunity costs of leaving and the nonpecuniary benefits of staying at home. The findings highlight the role of self-employment in a developing country in the likelihood of emigration.
25
Broder, Michael S., Qiufei Ma, Tingjian Yan, Eunice Chang, Lamis K. Eldjerou, Yanni Hao, David Kuzan, and Jie Zhang. "Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States." Blood 134, Supplement_1 (November 13, 2019): 4719. http://dx.doi.org/10.1182/blood-2019-122587.
Full textAbstract:
Introduction: Chimeric antigen receptor T (CAR-T) cell therapies targeting CD19 antigen can yield durable remissions in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Yet the use of CAR-T can be limited by potentially severe toxicities, principally cytokine release syndrome (CRS) and neurologic toxicities. Management of neurologic toxicities requires vigilant monitoring, supportive treatment and resource allocation. We found no studies reporting healthcare costs associated with treatment-related neurologic adverse events (NEAEs) in r/r DLBCL patients. The objective of this study was to develop an evidence-based list of r/r DLBCL treatment-related NEAEs and to estimate the healthcare costs associated with these NEAEs in a real-world setting. Methods: Grade 3 or higher NEAEs that occurred in ≥2% of patients were identified by reviewing U.S. drug prescribing information (PI), European Medicines Agency summaries of product characteristics, and published clinical trials for treatments of r/r DLBCL. Then, adult patients ≥18 years old with r/r DLBCL were identified from a U.S. administrative claims database containing de-identified claims for over 150 million people across over 11 years. Patients were included if they had: 1) evidence of treatment beyond first-line (2L+) during the identification period (07/01/14 - 12/31/18); and 2) ≥1 inpatient or ≥2 outpatient claims for DLBCL (ICD-9-CM codes: 200.7X; ICD-10-CM codes: C83.3X) during the study period (01/01/14 - 12/31/18) with ≥1 having occurred prior to or on the date when the 2L+ treatment was received. 2L+ treatments were selected based on National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines and clinical expert input. To maximize the identification of patients treated with CAR-T, treatments were categorized hierarchically into 4 groups: CAR-T therapy (axicabtagene ciloleucel, or tisagenlecleucel), high-intensity cytotoxic therapy (carboplatin, cisplatin, cyclophosphamide, or ifosfamide), low-intensity cytotoxic therapy (bendamustine, lenalidomide, or gemcitabine), and targeted monotherapy (rituximab, ibrutinib, or brentuximab vedotin). The index date was defined as the start date of the 2L+ treatment. Patients in the cytotoxic and targeted therapy groups were also required to have evidence of an earlier line of cytotoxic or targeted therapy. All patients were required to have ≥6-months continuous enrollment before the index date. The outcomes of interest were the rates of NEAEs and total healthcare costs for patients with and without NEAEs during the 30-day post index period. Costs were inflated to 2018 US dollars. Descriptive statistics were reported. Results: Twenty-three NEAEs were identified based on the review: 17 for CAR-T, 10 for conventional immunochemotherapy regimens, and 4 for both. In the claims database, a total of 349 adult patients with r/r DLBCL were identified, including 27 CAR-T therapy, 262 high-intensity cytotoxic therapy, 50 low-intensity cytotoxic therapy, and 10 targeted therapy users. Mean (median, SD) patient age was 72.3 (73; 10.3) years, with 47.9% being female and 83.4% having Medicare insurance. Patients were mainly from the South (44.1%) and the Midwest (31.5%). The mean (SD) Charlson comorbidity index was 4.4 (3.6) and mean (SD) number of chronic conditions was 7.3 (2.2). Forty-five (12.9%) patients had ≥1 NEAE at some point during the 30-day post-index period. Of these, 14 (31.1%) were CAR-T users. Eleven (40.7%) of the CAR-T users had encephalopathy. Mean total healthcare costs were $99,611 higher for patients with NEAEs [mean (SD): $153,435 (227,771)] than those without any NEAEs [$53,824 (96,170)]. Among patients with NEAEs, 72% of the healthcare costs were accrued in the inpatient setting. Among patients without NEAEs, 63% of the healthcare costs were for outpatient medical services. The trend of higher costs in patients with NEAEs was consistent across treatment groups. Conclusion: This is the first study of the economic burden of NEAEs associated with treating r/r DLBCL in a real-world setting with data that reflects the current range of treatment options. Patients with r/r DLBCL who have NEAEs incur substantially higher costs than those without such events. In this analysis, CAR-T is overrepresented for NEAEs, although the sample size is small. We intend to repeat the analysis when more claims data becomes available in the near future. Disclosures Broder: Partnership for Health Analytic Research (PHAR), LLC: Other: I am an employee of the Partnership for Health Analytic Research (PHAR), LLC, which was paid by Novartis to conduct the research described in this abstract.. Ma:Novartis Pharmaceuticals Corporation: Employment. Yan:Partnership for Health Analytic Research (PHAR), LLC: Other: T. Yan is an employee of Partnership for Health Analytic Research (PHAR), LLC, a health services research company paid to conduct this research.. Chang:Partnership for Health Analytic Research (PHAR), LLC: Other: E. Chang is an employee of Partnership for Health Analytic Research (PHAR), LLC, a health services research company paid to conduct this research.. Eldjerou:Novartis Pharmaceuticals Corporation: Employment. Hao:Novartis Pharmaceuticals Corporation: Employment, Equity Ownership. Kuzan:Novartis Pharmaceuticals Corporation: Employment. Zhang:Novartis Pharmaceuticals Corporation: Employment, Equity Ownership.
26
Fairlie, Robert W., Dean Karlan, and Jonathan Zinman. "Behind the GATE Experiment: Evidence on Effects of and Rationales for Subsidized Entrepreneurship Training." American Economic Journal: Economic Policy 7, no. 2 (May 1, 2015): 125–61. http://dx.doi.org/10.1257/pol.20120337.
Full textAbstract:
Theories of market failures and targeting motivate the promotion of entrepreneurship training programs and generate testable predictions regarding heterogeneous treatment effects from such programs. Using a large randomized evaluation in the United States, we find no strong or lasting effects on those most likely to face credit or human capital constraints, or labor market discrimination. We do find a short-run effect on business ownership for those unemployed at baseline, but this dissipates at longer horizons. Treatment effects on the full sample are also short-term and limited in scope: we do not find effects on business sales, earnings, or employees. (JEL I26, J24, J68, L25, L26, M13)
27
Oriakhogba, Desmond Osaretin. "What If DABUS Came to Africa? Visiting AI Inventorship and Ownership of Patent from the Nigerian Perspective." Business Law Review 42, Issue 2 (April 1, 2021): 89–99. http://dx.doi.org/10.54648/bula2021013.
Full textAbstract:
Dr Stephen Thaler’s artificial intelligent machine – DABUS (Device for the Autonomous Bootstrapping of Unified Sentience) recently created two patentable devises that were the subject of patent applications in the European Patent Office (EPO), the United Kingdom Intellectual Property Office (UKIPO), the United States Patent and Trademark Office (USPTO) and other patent offices, including under the Patent Cooperation Treaty system. Thaler named DABUS as the inventor in the applications and claimed to have acquired the right to patent from DABUS as its owner, employer and successor in title. The EPO, UKIPO and USPTO recently rejected the applications on the ground of non-compliance with the formal requirements of their respective patent legislation for failing to name a natural person as inventor. Based on a comparative study conducted as a desk research, the paper reviews the EPO, UKIPO and USPTO decisions against the backdrop of the ongoing policy and academic conversations on AI and patent policy. It then situates the decisions within the African context, especially under the Nigerian patent regime, and determines whether the Nigerian patent office will reach a different conclusion from those made by the EPO, UKIPO and USPTO should a similar patent application be considered in Nigeria. Artificial Intelligence, Inventorship, Patent Regimes, DABUS, EPO, UKIPO, USPTO, Nigeria
28
Dreitz, Victoria J., Lani T. Stinson, Beth A. Hahn, Jason D. Tack, and Paul M. Lukacs. "A large-scale perspective for managing prairie avifauna assemblages across the western US: influences of habitat, land ownership and latitude." PeerJ 5 (January 18, 2017): e2879. http://dx.doi.org/10.7717/peerj.2879.
Full textAbstract:
Future demands for increased food production are expected to have severe impacts on prairie biodiversity and ecosystem integrity. Prairie avifauna of North America have experienced drastic population declines, prompting numerous conservation efforts, which have been informed primarily by small-scale studies. We applied a large-scale perspective that integrates scale dependency in avian responses by analyzing observations of 20 prairie bird species (17 grassland obligates and three sagebrush obligate species) from 2009–2012 in the western prairie region of the United States. We employed a multi-species model approach to examine the relationship of land ownership, habitat, and latitude to landscape-scale species richness. Our findings suggest that patterns and processes influencing avian assemblages at the focal-scale (e.g., inference at the sampling unit) may not function at the landscape-scale (e.g., inference amongst sampling units). Individual species responses to land ownership, habitat and latitude were highly variable. The broad spatial extent of our study demonstrates the need to include lands in private ownership to assess biodiversity and the importance of maintaining habitat diversity to support avian assemblages. Lastly, focal-scale information can document species presence within a study area, but landscape-scale information provides an essential complement to inform conservation actions and policies by placing local biodiversity in the context of an entire region, landscape or ecosystem.
29
Shang, Jingjing, Ashley Chastain, U. Gayani Perera, Monika Pogorzelska-Maziarz, and Patricia Stone. "Infection Prevention and Control Policies and Staffing: A National Survey of Home Health Agencies in the United States." Infection Control & Hospital Epidemiology 41, S1 (October 2020): s301. http://dx.doi.org/10.1017/ice.2020.882.
Full textAbstract:
Background: Infection prevention and control (IPC) is a national priority in all healthcare settings, and IPC staffing characteristics have been linked to patient safety outcomes. However, there is a lack of knowledge about IPC in home healthcare (HHC), the fastest growing healthcare sector. Our aim was to better understand the current state of IPC in HHC, as well as the HHC staff involved with IPC policy implementation. Methods: A national survey was conducted between October 2018 and November 2019. The participants included (1) agencies recruited from a national HHC conference and (2) a national random sample of 1,501 agencies stratified by census region, ownership status, and rural or urban location. Survey items included staff influenza vaccination policies, antibiotic stewardship, infection surveillance, and IPC staffing. Descriptive statistics were computed, and differences by ownership were calculated using 2 and Student t tests. Results: Of the 535 HHC agencies that responded to the survey (response rate, 33%), 64% were for-profit agencies. Overall, 30.8% of the agencies (17.9% for-profit, 57.6% nonprofit; P < .01) required staff influenza vaccination. Most nonprofit agencies (84.1%) and about half of the for-profit agencies (48.1%) offered free influenza vaccinations to staff (P < .01). During the past influenza season, 62.6% of agencies (81.5% nonprofit vs 51.6% for-profit; P < .01) had 75% of their employees vaccinated for influenza, and 9.3% (2% nonprofit vs 13.5% for-profit; P < .01) reported that they did not track this data. Only 17.9% of HHC agencies used antibiotic prescribing guidelines, and 33.3% reported that they reviewed cases to assess the appropriateness of antibiotic administration and/or indication. Most HHC agencies (86%) reported collecting and reviewing infection data to identify trends, which was often done quarterly or more frequently. Almost every responding agency reported that the staff member in charge of IPC had other responsibilities including administrative, education/training, or quality improvement, and 33.5% of those personnel had received no specific IPC training. Also, ~6% of agencies (12.5% of government-owned agencies) reported that they currently did not have a staff member in charge of IPC. Conclusions: This is the first national study of IPC in HHC, which can be used as a benchmark for quality improvement initiatives in the home care environment. Compared to other healthcare settings, HHC agencies have substantial challenges related to IPC. Most HHC agencies do not have a staff member exclusively dedicated to IPC, and staff training is inadequate. Furthermore, a significant number of agencies have no staff influenza vaccination or antibiotic stewardship policies in place. The situation is worse at for-profit agencies, which dominate the current US HHC industry.Funding: NoneDisclosures: None
30
Parasuraman, Shreekant V., Ahmad B. Naim, Dilan C. Paranagama, Maureen Thyne, Sara Goldberger, John O. Mascarenhas, James Mangan, Salman Fazal, Carole B. Miller, and Ruben A. Mesa. "Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States." Blood 126, no. 23 (December 3, 2015): 5561. http://dx.doi.org/10.1182/blood.v126.23.5561.5561.
Full textAbstract:
Abstract Background: Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms (MPNs). Patients across all 3 MPNs experience marked disease burden in terms of symptoms and negative effects on quality of life (QoL), productivity, and activities of daily living (ADL). To improve the lives and health of patients with MPNs, it is also important to have a current understanding of these burdens from a financial standpoint. This analysis of MPN Landmark survey data examined the financial burden of patients who reported that their MPN affected their employment (ie, reduced work hours, discontinued employment, or went on medical disability) or experienced no such effects on their employment. Methods: Patients diagnosed with MF, PV, or ET were recruited to participate in a real-world retrospective study (MPN Landmark survey) in the US (fielded May - July 2014). Only respondents who were diagnosed before 2013 and were 16 to 65 years of age at the time of diagnosis were eligible for this analysis. Participants were asked if their MPN had an impact in terms of reduced work hours, discontinued employment, medical disability, or no impact; the first 3 categories were not mutually exclusive. Participants provided information on their annual household income in 2013 before taxes by selecting from the following categories: ≤$15,000, $15,001-$25,000, $25,001-$35,000, $35,001-$50,000, $50,001-$75,000, $75,001-$100,000, and >$100,000. The mid value of each range was used to calculate mean income levels within each subgroup evaluated. Results: A total of 813 patients completed the web-based Landmark survey and 369 eligible patients were included in this analysis (MF, 85; PV, 172; ET, 112). Median age among patients with ET was slightly lower than among patients with MF and PV at time of MPN diagnosis (ET, 48 years; MF, 56 years; PV, 53 years). The majority of respondents were women (MF, 62%; PV, 52%; ET, 75%). Almost all patients (99%) had health insurance, primarily group commercial insurance through an employer (MF, 46%; PV, 53%; ET, 57%) and Medicare (MF, 40%; PV, 34%; ET, 24%). Most patients had at least some college education (ie, some college, 4-year degree, or postgraduate degree): MF, 86%; PV, 90%; ET, 88%. The mean 2013 household income of patients with MF, PV, and ET were similar to each other ($79,800, $80,200, and $80,400, respectively) and slightly higher than the total 2013 US mean household income of $75,839. A notable proportion of patients in each MPN group reported that their disease led to reduced work hours, discontinued employment, and medical disability: MF, 38%, 35%, and 33%, respectively; PV, 33%, 28%, and 15%; ET, 28%, 21%, and 4%. Patient demographics, such as age and health insurance status, were similar among patients who reported MPN-associated effects on employment and patients who did not within each MPN. In each MPN group, the mean percentage household income loss in patients with reduced work hours, discontinued employment, and medical disability were: MF, 16%, 18%, and 28%, respectively; PV, 15%, 24%, and 17%; and ET, 0%, 24%, and 37%, compared with patients who did not experience any effects of their MPN on employment (Figure 1). Discontinued employment and medical disability tended to have a greater impact compared with reduced work hours across MPNs. Conclusion: Patients withMPNs may experience a considerable negative impact on their employment status, which in turn may be associated with reduced annual household income. Therefore, across all MPNs, forestalling or reversing discrete aspects of the diseases that negatively impact individual productivity is an important factor in the management of these chronic neoplasms. Disclosures Parasuraman: Incyte Corporation: Employment, Equity Ownership. Naim:Incyte Corporation: Employment, Equity Ownership. Paranagama:Incyte Corporation: Employment, Equity Ownership. Thyne:Incyte Corporation: Speakers Bureau. Mascarenhas:Incyte Corporation: Research Funding; Novartis Pharmaceuticals Corporation: Research Funding; Promedior: Research Funding; Roche: Research Funding; CTI Biopharma: Research Funding; Kalobios: Research Funding. Mangan:Incyte Corporation: Membership on an entity's Board of Directors or advisory committees. Fazal:Bristol Myers Squibb: Consultancy, Honoraria, Speakers Bureau; Ariad: Consultancy, Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau. Miller:Incyte Corporation: Honoraria, Research Funding. Mesa:Promedior: Research Funding; Gilead: Research Funding; Incyte Corporation: Research Funding; NS Pharma: Research Funding; CTI Biopharma: Research Funding; Novartis Pharmaceuticals Corporation: Consultancy; Genentech: Research Funding; Pfizer: Research Funding.
31
Zhu, Xiaolin, and Desheng Liu. "Investigating the Impact of Land Parcelization on Forest Composition and Structure in Southeastern Ohio Using Multi-Source Remotely Sensed Data." Remote Sensing 11, no. 19 (September 20, 2019): 2195. http://dx.doi.org/10.3390/rs11192195.
Full textAbstract:
Forestland parcelization (i.e., a process by which large parcels of forestland ownership are divided into many small parcels) presents an increasing challenge to sustainable forest development in the United States. In Southeastern Ohio, forests also experienced intensive forestland parcelization, where the majority of forest owners own parcels smaller than 10 acres currently. To better understand the impact of forestland parcelization on forest development, this study employed multi-source remotely sensed data and land ownership data in Hocking County, Ohio to examine the relationship between forestland parcel size and forest attributes, including forest composition and structure. Our results show that private forestland parcels are generally smaller than public forestland (the average parcel sizes are 21.5 vs. 275.0 acres). Compared with private lands, public lands have higher values in all forest attributes, including forest coverage, abundance of oak-dominant stands, canopy height and aboveground biomass. A further investigation focusing on private forestland reveals that smaller parcels tend to have smaller forest coverage, less greenness, lower height and aboveground biomass, indicating that forests in smaller parcels may experience more human disturbances than larger parcels. The results also show that logarithmic models can well quantify the non-linear relationship between forest attributes and parcel size in the study area. Our study suggests that forestland parcelization indeed has negative effects on forest development, so it is very important to take appropriate measures to protect forests in small ownership parcels.
32
Gaspareniene, Ligita, Greta Gagyte, Rita Remeikiene, and Snieguole Matuliene. "Clustering of the European Union member states based on money laundering measuring indices." Economics & Sociology 15, no. 2 (2022): 153–71. http://dx.doi.org/10.14254/2071-789x.2022/15-2/10.
Full textAbstract:
The number of enforcement actions and fines for non-compliance with anti-money laundering (AML) regulations continues climbing year after year, and the year 2021 was no exception to this tendency. Globally, authorities remain harsh, and AML fines in Europe, the United States, and the United Kingdom have been increasing (Global Anti-Money Laundering Regulations, 2021). According to the UN estimations, the amount of money annually laundered worldwide amounts to 2–5% of the world’s Gross Domestic Product (GDP), or in absolute numbers - to 800 billion-2 trillion US dollars. Such high figures indicate that national governments are indeed facing a serious problem of money laundering. In this article, clustering is employed to group the EU member states by their money laundering measuring indices in order to assess the EU legal framework in terms of money laundering prevention. State clustering could help the relevant EU institutions, such as Financial Intelligence Units (FIUs), Europol, International Monetary Fund (IMF), national governments and others, to develop the most effective measures to diminish the problem of money laundering and to complement their regulatory framework. Money laundering is usually associated with criminal activities that generate large amounts of illegal financial resources. In the most general sense, money laundering refers to the process of disguising the true origin, ownership, disposal and movement of particular proceeds, property or property rights. The results of the empirical research propose that money laundering reduction calls for a higher number of suspicious transaction reports (STRs), lower levels of corruption and improvement of the legal framework in terms of money laundering prevention in the EU. The research methods cover comparative and systematic literature analysis, and hierarchical cluster analysis. The cluster analysis of the EU member states (28 countries) uses the number of reports filled with FIU between 2006-2014, the 2012-2020 Basel AML Index and the 1998-2018 CPI data.
33
Fola Ayokanmbi, Rolandrea Russell, and Jacob Oluwoye. "The study of employment location and transportation accessibility in the Huntsville Metropolitan area." International Journal of Science and Research Archive 2, no. 2 (June 30, 2021): 183–93. http://dx.doi.org/10.30574/ijsra.2021.2.2.0068.
Full textAbstract:
The main purpose of a transportation system is to connect people to their communities and specifically to connect employees to jobs. The Huntsville Metropolitan region’s transportation system is without a doubt almost exclusively automobile dependent due to the limited availability of public transportation along with the Regions’ 2000 and 2010 Metropolitan Planning Organization (MPOs). Journey to work report. In an automobile dependent region, the level of car ownership is crucial in determining accessibility as well as the ability to utilize employment opportunities. Increased job decentralization and suburban employment throughout various metropolitan areas across the United States decreases the level of employment accessibility resulting in the need for efficient accessibility to the existing transportation system and employment opportunities. Employment accessibility is an issue of great concern in urban areas across the United States significantly in major metropolitans, which is evident based on the continued study, evaluation, analysis, and scrutiny by numerous scholars. In evaluating employment accessibility, the concept of automobile dependency is a relevant factor for the presence of spatial and/or modal mismatch. The purpose of this paper therefore is to examine the relationship between transportation accessibility and employment location in the metropolitan area of Huntsville, Alabama. In doing this the author examines the attributes of residential location, car ownership, house value and other demographic factors of the Huntsville, Metropolitan region to answer the research question of “what, if any is the relationship between these attributes and factors?” Data was obtained from the US Census Bureau for the 2000 and 2010 periods and was extracted then exported and saved as an SPSS document where it was manipulated and analyzed. The Pearson Product Moment correlation coefficients (r) were calculated to give an indication of the suggested relationships between variables as the author assesses the employment accessibility in the Huntsville Metropolitan Region. The number of vehicles available which reflects the level of car ownership within the sample is positively related to the residential location indicating that one’s residential location is indeed related to owning a car. This paper concludes that spatial mismatch encompasses the economic restructuring of the Huntsville Metropolitan Region’s whereby employment opportunities are located far away from areas of residence. Modal mismatch is due to the challenges and/or inabilities faced by individuals in their travels between home and work or place of potential employment.
34
Shaheen, Susan A., and Caroline J. Rodier. "Travel Effects of a Suburban Commuter Carsharing Service." Transportation Research Record: Journal of the Transportation Research Board 1927, no. 1 (January 2005): 182–88. http://dx.doi.org/10.1177/0361198105192700121.
Full textAbstract:
Since 1998, carsharing organizations in the United States have experienced exponential membership growth, but to date there have been only a few evaluations of their effects on travel. Using the results of focus groups, interviews, and surveys, this paper examines the change in travel among members of CarLink–-a carsharing model in the San Francisco Bay Area, California, with explicit links to transit and suburban employment–-after approximately 1 year of participation. The demographic and attitudinal analyses of CarLink members indicated that the typical member ( a) was more likely than an average Bay Area resident to be highly educated, in an upper income bracket, and professionally employed and ( b) displayed sensitivity to congestion, willingness to try new experiences, and environmental concern. Some of the more important commuter travel effects of the CarLink programs included an increase in rail transit use by 23 percentage points in CarLink I and II; a reduction in driving without passengers by 44 and 23 percentage points in CarLink I and II, respectively; a reduction in average vehicle miles traveled by 23 mi in CarLink II and by 18 mi in CarLink I; an increase in travel time and a reduction in travel stress; a reduction in vehicle ownership by almost 6% in CarLink II; and reduced parking demand at participating train stations and among member businesses. The CarLink travel results are compared with those of neighborhood carsharing models in the United States and Europe.
35
Swan, Daniel C., and Mary S. Linn. "A Language Fair, a Community and a Museum." Museum Anthropology Review 15, no. 1 (September 13, 2021): 54–70. http://dx.doi.org/10.14434/mar.v15i1.32105.
Full textAbstract:
Founded in 2003 the Oklahoma Native American Youth Language Fair (ONAYLF) has become one of the largest gatherings of Native American language learners in the United States. The Fair is unquestionably the most significant and sustained interaction with Native American communities in the history of the Sam Noble Museum, quickly becoming a signature event that contributes to the museum’s reputation and stature. As the Fair gained increased prominence and importance in the Native American communities of Oklahoma and the surrounding regions it was consistently marginalized within the institutional culture of the museum. Over the course of our respective leadership of the ONAYLF we encountered the continued need for anthropological intervention to “re-institutionalize” a very successful program. In this report we focus on specific impacts of this failed ownership and the anthropological methods employed to address them. We conclude with an assessment of the ONAYLF in terms of on-going efforts to decolonize museum practice.
36
Fazal, Salman, Carole B. Miller, John O. Mascarenhas, Maureen Thyne, Sara Goldberger, Dilan C. Paranagama, Shreekant V. Parasuraman, Ahmad B. Naim, James Mangan, and Ruben A. Mesa. "Phlebotomy Frequency and Quality of Life and Productivity in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States." Blood 126, no. 23 (December 3, 2015): 5184. http://dx.doi.org/10.1182/blood.v126.23.5184.5184.
Full textAbstract:
Abstract Background: Phlebotomy is a common and established treatment in patients diagnosed with polycythemia vera (PV) to reduce the risk of thromboembolic events, in both acute and chronic settings. However, phlebotomy may not alleviate all PV-related symptoms and its frequent application can cause moderate to profound iron deficiency, which may worsen PV-related symptoms. This analysis of MPN Landmark survey data examined patient-reported quality of life (QoL) and productivity outcomes in patients with PV based on phlebotomy treatment history. Methods: Patients who were diagnosed with a myeloproliferative neoplasm (MPN) were recruited to participate in the MPN Landmark survey in the US (fielded May - July 2014). This analysis describes responses from patients with PV on questions regarding PV-related symptom burden, QoL, and productivity. Patient responses were analyzed based on phlebotomy treatment history and included patients who were actively receiving phlebotomy within the last 3 months (≥1 per month, every other month, and every 3 months or longer), had discontinued phlebotomy, or were phlebotomy-naive. Descriptive statistical analyses were used to evaluate these outcomes based on phlebotomy frequency, as appropriate. Results: Overall, 813 patients completed the Landmark survey, and 274 out of the 380 patients with PV who completed the survey were evaluable for this analysis. Mean age ranged from 61.6-65.4 years among phlebotomy subgroups (Table 1). The average duration of PV was longest among patients with PV who had discontinued phlebotomy (12.0 years) compared with phlebotomy-naive patients (6.3 years) and patients actively treated with phlebotomy (5.9-8.9 years). The percentage of patients diagnosed within 1 year of the survey ranged from 4.1% to 11.5% among the patients who had been treated with phlebotomy and was 15.4% in the phlebotomy-naive subgroup. Most patients reported PV-related symptoms; symptom burden was similar in all phlebotomy subgroups. Fatigue was the most common symptom reported in all subgroups (range, 71.4%-80.8%). QoL measures were generally worse with higher phlebotomy frequency (Table 1). Similarly, more frequent phlebotomy procedures was found to be associated with reduced productivity: patients who received ≥1 phlebotomy per month had the highest mean number (in the preceding 30 days) of sick days (among patients employed), days spent in bed, and days with plans canceled. Of note, approximately one third of patients receiving more frequent phlebotomy procedures were also receiving concomitant hydroxyurea to manage their PV (≥1 per month, 38.5%; every other month, 36.4%). Conclusion: Patients with PV may experience disease-related symptoms and reductions in QoL and work productivity. Frequent phlebotomy procedures were associated with increasingly worsened QoL and decreased work productivity. Further research is needed to better understand the impact of phlebotomy on patient-reported outcomes in patients with PV. Disclosures Fazal: Bristol Myers Squibb: Consultancy, Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; Ariad: Consultancy, Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau. Miller:Incyte Corporation: Honoraria, Research Funding. Mascarenhas:Promedior: Research Funding; Roche: Research Funding; CTI Biopharma: Research Funding; Kalobios: Research Funding; Novartis Pharmaceuticals Corporation: Research Funding; Incyte Corporation: Research Funding. Thyne:Incyte Corporation: Speakers Bureau. Paranagama:Incyte Corporation: Employment, Equity Ownership. Parasuraman:Incyte Corporation: Employment, Equity Ownership. Naim:Incyte Corporation: Employment, Equity Ownership. Mangan:Incyte Corporation: Membership on an entity's Board of Directors or advisory committees. Mesa:Promedior: Research Funding; Genentech: Research Funding; Gilead: Research Funding; NS Pharma: Research Funding; Novartis Pharmaceuticals Corporation: Consultancy; CTI Biopharma: Research Funding; Pfizer: Research Funding; Incyte Corporation: Research Funding.
37
Chen, Lei, Dominick Latremouille-Viau, Annie Guerin, Roy Nitulescu, and Patrick Gagnon-Sanschagrin. "Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis." Blood 126, no. 23 (December 3, 2015): 1596. http://dx.doi.org/10.1182/blood.v126.23.1596.1596.
Full textAbstract:
Abstract Background: To date, no studies have directly compared the treatment patterns and economic outcomes of dasatinib and nilotinib as 1st-line therapy for Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). This study aimed to address this gap using retrospective claims data. Method: Newly diagnosed adult pts with CML who received dasatinib or nilotinib as 1st-line therapy were identified from 2 large US administrative claims databases (Q1/2010 - Q4/2014). Pts with continuous health plan coverage for ≥6 months before (baseline period) and ≥1 month after the 1st-line TKI initiation (index date) were classified as dasatinib or nilotinib pts based on the 1st-line TKI. Pts were excluded from the study if they were enrolled in a clinical trial, had a stem-cell transplant, received chemotherapy (except hydroxyurea), had a metastatic cancer/solid tumor or end stage renal disease during the baseline period. Dose adjustment (dose decrease/increase of ≥20mg for dasatinib and ≥100mg for nilotinib vs the initial dose) were measured from the index date to treatment discontinuation (i.e., treatment gap of ≥60 days) or end of follow-up. Treatment adherence was measured using proportion of days covered (PDC) during a 6- and 12-month period following index date among pts with continuous health plan coverage during these periods. Treatment discontinuation, switching to another TKI, and healthcare resource utilization (HRU) and costs (pharmacy+medical costs; per person per month: PPPM; USD 2014) were measured from index date to end of follow-up. Outcomes were compared between cohorts using multivariate regression analyses adjusting for potential confounding factors identified at baseline/index date (age, gender, CML complexity, CCI, starting dose, and health plan type). Results: A total of 604 dasatinib and 418 nilotinib pts met the sample selection criteria with average follow-up of 17 months in both cohorts. Pts in dasatinib and nilotinib cohorts did not significantly differ in age (mean=51 vs 52, respectively; p=.114), sex (46% female in both cohorts; p=.834), and comorbidities (mean CCI=1.4 vs 1.5, respectively; p=.600). In dasatinib pts, 91% started with 100mg/day, 3% with <100mg/day, and 6% with 140mg/day. In nilotinib pts, 76% started with 600mg/day, 16% with 800mg/day, and 8% <600mg/day. Dasatinib pts had a higher risk of dose decrease compared to nilotinib pts (crude rate: dasatinib=19%, nilotinib=15%; adjusted hazard ratio [HR]=1.66; p=.002). There was no significant difference in risk of dose increase between cohorts (crude rate: dasatinib= 3%, nilotinib= 4%; adjusted HR=0.76; p=.423). Dasatinib and nilotinib pts had similar adherence levels during the first 6-month (mean PDC: dasatinib =87% [N=481], nilotinib=86% [N=333]; adjusted difference= -0.03%; p=.981) and 12-month periods (mean PDC: dasatinib=78% [N=343], nilotinib=78% [249]; adjusted difference = -0.22%; p=.880). There was no significant difference in risk of treatment discontinuation between cohorts (crude rate: 39% in both cohorts; adjusted HR=1.10; p=.372). Dasatinib pts had higher risk of switching compared to nilotinib pts (crude rate: dasatinib=13%, nilotinib=9%; adjusted HR=1.62; p=.019). Pts had similar HRU; average number of inpatient days, emergency room visits, and outpatient visits PPPM were 0.13 vs 0.16 (adjusted incidence rate ratio [IRR]=1.03; p=.930), 0.06 vs 0.04 (adjusted IRR=1.26; p=.197), and 1.91 vs 1.95 (adjusted IRR=1.01; p=.842) for dasatinib vs nilotinib pts, respectively. Dasatinib pts incurred higher healthcare costs by $749 PPPM compared to nilotinib pts (adjusted incremental costs; p=.044; average healthcare costs PPPM: dasatinib=$10,341, nilotinib=$9,611). Conclusions: Based on retrospective claims data, this study shows that dasatinib was associated with an increased risk of dose decrease despite majority of pts starting on the recommended dose, an increase risk of switching to another TKI, and higher total healthcare costs compared to nilotinib pts. No difference in adherence, discontinuation, and HRU was found. The study showed the association between nilotinib versus dasatinib as first-line therapy in CML patients and outcomes, not causation. The proportion of CML patients in accelerated phase or blast crisis by cohort at the first-line TKI initiation and its impact on results is unknown but was assumed to be marginal. Disclosures Chen: Novartis Pharmaceuticals Corporation: Employment, Equity Ownership. Latremouille-Viau:Janssen-Cilag GmbH, Janssen-Ortho, Inc., Merck Frosst Canada, Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Janssen Scientific Affairs, LLC, Centocor Ortho Biotech: Consultancy, Other: Dominick Latremouille-Viau is an employee of Analysis Group Inc, which has received consultancy fees from the listed organizations; AbbVie Inc., Alcon Laboratories, AstraZeneca, Bayer Healthcare Pharmaceuticals, LLC, Celgene Corporation, Forest Laboratories, Inc., Genentech, Inc., GlaxoSmithKline: Consultancy, Other: Dominick Latremouille-Viau is an employee of Analysis Group Inc, which has received consultancy fees from the listed organizations; Pfizer Canada, Inc., Savient Pharmaceuticals, Inc., Shire Pharmaceuticals Inc., Takeda Global Research & Development Center, Inc.,Takeda Pharmaceuticals U.S.A., Inc.: Consultancy, Other: Dominick Latremouille-Viau is an employee of Analysis Group Inc, which has received consultancy fees from the listed organizations. Guerin:GlaxoSmithKline, Janssen Scientific Affairs, Janssen-Ortho, Inc., Merck & Co., Inc., Merck Frosst Canada, Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Ogilvy Renault, Ortho-Clinical Diagnostics, Inc., Otsuka America Pharmaceutical, Inc.,: Consultancy, Other: Annie Guerin is an employee of Analysis Group Inc, which has received consultancy fees from the listed organizations; Pfizer Canada, Inc., RX&D, Sanofi, Savient Pharmaceuticals, Inc., Shire Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Takeda Global Research & Development Center, Inc., Takeda Pharmaceuticals U.S.A., Inc.: Consultancy, Other: Annie Guerin is an employee of Analysis Group Inc, which has received consultancy fees from the listed organizations; AbbVie Inc., Alcon Laboratories, Bayer Healthcare Pharmaceuticals, LLC, Celgene Corporation, Cempra Inc., Centocor Ortho Biotech, Cooley LLP, Cyberonics, Inc., DLA Piper, Eli Lilly & Company, Forest Laboratories, Inc., Genentech, Inc.,: Consultancy, Other: Annie Guerin is an employee of Analysis Group Inc, which has received consultancy fees from the listed organizations. Nitulescu:Novartis Pharmaceuticals Corporation, Sunovion Pharmaceuticals Inc., AbbVie Inc., Otsuka America Pharmaceutical, Inc., Shire Pharmaceuticals Inc., Genentech, Inc., GlaxoSmithKline, Merck Frosst Canada: Consultancy, Other: Roy Nitulescu is an employee of Analysis Group Inc, which has received consultancy fees from the listed organizations. Gagnon-Sanschagrin:Novartis Pharmaceuticals Corporation, Genentech, Inc., AbbVie Inc., Takeda Pharmaceuticals U.S.A., Inc.: Consultancy, Other: Patrick Gagnon-Sanschagrin is an employee of Analysis Group Inc, which has received consultancy fees from the listed organizations.
38
Lopez Jaramillo, Oscar, Rhian Stotts, Scott Kelley, and Michael Kuby. "Content Analysis of Interviews with Hydrogen Fuel Cell Vehicle Drivers in Los Angeles." Transportation Research Record: Journal of the Transportation Research Board 2673, no. 9 (May 8, 2019): 377–88. http://dx.doi.org/10.1177/0361198119845355.
Full textAbstract:
Hydrogen fuel cell vehicles (HFCVs) are zero-emission vehicles (ZEVs) and their widespread adoption may help to mitigate some of the issues arising from fossil-fuel usage in the transportation sector. Only in recent years have these vehicles become available for purchase or lease in the United States, and only within the State of California. In 2018, nearly 5,500 HFCVs had been sold or leased in California, supported by a developing refueling infrastructure there. This population represents a unique opportunity, as previous studies on HFCV adoption have largely employed hypothetical stated preference surveys distributed to likely adopters. Seeking to investigate the real experiences of actual adopters from their own perspectives, semi-structured interviews were conducted with 12 early adopters of HFCVs in the Los Angeles metropolitan area. Thematic content analysis of these interviews was conducted to identify the prevalence of factors deductively derived from published literature. All respondents considered lifetime cost of vehicle ownership, engaged in comparison shopping, and assessed the adequacy of the refueling infrastructure by various geographical criteria. Environmental concerns motivated many respondents to pursue HFCV adoption, though only if it made financial sense. Respondents chose HFCVs over battery electric vehicles after consideration of range, refueling time, and cost. Early HFCV adopters consistently cast their adoption of the technology as a contribution to a diverse ZEV marketplace. Strategies for the promotion of HFCV technology must account for this range of variation in early-adopter motivations, concerns, and behaviors which might complicate targeted HFCV promotion strategies.
39
Condliffe, Simon, Jingbo Yu, Dilan Chamikara Paranagama, and Shreekant Parasuraman. "Impact of Myeloproliferative Neoplasms on Patients' Employment and Income: Findings from the Living with MPN Survey." Blood 132, Supplement 1 (November 29, 2018): 2250. http://dx.doi.org/10.1182/blood-2018-99-115345.
Full textAbstract:
Abstract Background: Patients with myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), experience a high symptom burden that may compromise daily functioning and quality of life. The objective of this analysis was to evaluate income loss associated with disease-related employment changes among patients with MPNs in the United States. Methods: The Living with MPN survey was completed online by adult patients (aged 18-70 years) with MF, PV, or ET in the United States between April and November of 2016. Respondents employed at the time of MPN diagnosis were asked questions about disease-related changes in employment status and salaries occurring between diagnosis and the year of survey (2016). In addition, details related to patient demographics, MPN diagnosis, and MPN-related symptoms were collected. Cumulative income losses as a result of disease-related employment changes up to the time of the survey were calculated based on the timing of employment changes and salaries, which were reported in nominal dollars. Results: Of the 904 survey respondents, 592 (65%) were employed at the time of MPN diagnosis. Among those employed, mean age was 54.0 years, 70.6% were female, and 72.3% were married or had domestic partners at the time of survey. The average duration of disease was 6.1 years (MF, 4.6; PV, 6.9; ET, 6.3). Approximately half (50.5%) of the employed respondents experienced at least one change in employment status because of their diagnosis. Employment status changes and associated impact on income in patients with MPNs was greatest for those who took early retirement, medical disability leave, or left a job due to their disease ($419,610, $169,048, $168,245, respectively). Respondents who changed from full- to part-time employment, reduced hours, or were reassigned to a lower-paying job because of their disease also reported income losses ($79,492, $47,104, $51,872, respectively; Table). Among respondents who were 45-64 years old at the time of the survey (n=383), 18.8% reported retiring early as a result of their disease. In comparison, according to nationally representative data from the Medical Expenditures Panel Survey (MEPS), only 7.8% of individuals aged 45-64 years in excellent or very good health and 9.2% of individuals in poor health reported being retired (longitudinal data set 2014-2015). Moreover, 30.5% (117/383) of respondents aged 45-64 years in the Living with MPN survey reported leaving a job as a result of their disease. In comparison, 5.5% of MEPS individuals aged 45-64 years in excellent or very good health and 16.4% of individuals in poor health were working at the start of 2014 but not by the end of 2015. Conclusions: About half of employed patients living with MPNs experienced a variety of employment changes as a result of their disease, which in turn had a considerable impact on income. The most frequently reported disease-related employment change was leaving a job, followed by medical disability leave, reduced hours, early retirement, switching from full-time to part-time, and being reassigned to a lower-paying job. Patients 45-64 years old with MPNs were more than twice as likely to have left a job or retired early compared with an age-matched US general population cohort. On average, the foregone income due to disease-related employment changes was greatest for early retirees ($419,610), followed by those who went on medical disability leave ($169,048), and left a job ($168,245). Early, effective management of MPNs and associated symptoms may help patients avoid these disease-related changes to their employment status and the subsequent economic and financial impact. Disclosures Condliffe: Incyte Corporation: Consultancy. Yu:Incyte Corporation: Employment, Equity Ownership. Paranagama:Incyte: Employment, Equity Ownership. Parasuraman:Incyte: Employment, Equity Ownership.
40
Cohen-Vogel, Lora, Marisa Cannata, Stacey A. Rutledge, and Allison Rose Socol. "A Model of Continuous Improvement in High Schools: A Process for Research, Innovation Design, Implementation, and Scale." Teachers College Record: The Voice of Scholarship in Education 118, no. 13 (April 2016): 1–26. http://dx.doi.org/10.1177/016146811611801301.
Full textAbstract:
This article describes a model for continuous improvement that guides the work of the National Center on Scaling Up Effective Schools, or NCSU. NCSU is a research and development center funded by the Institute for Education Sciences, the research arm of the United States Department of Education. At the core of the Center's work is an innovative process to bring to scale practices that have been shown to improve student achievement in high schools in Broward County, Florida, and Fort Worth, Texas. To do so, the Center's model of improvement relies on three core principles. First, a prototype is built to reflect the core elements of programs or practices that have been shown to be effective locally. Second, rapid-cycle testing is used to allow the prototype to be revised in ways that adapt it to a particular school context. Third, a researcher–practitioner partnership is employed that strives to both take advantage of and build local ownership and expertise. In so doing, the continuous improvement model addresses well-known challenges faced by those attempting to scale up educational innovations, challenges such as building teacher buy-in and attending to the organizational context in which innovations are to be enacted.
41
Mesa, Ruben, Carole B. Miller, Maureen Thyne, James Mangan, Sara Goldberger, Salman Fazal, Xiaomei Ma, et al. "Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States." Blood 124, no. 21 (December 6, 2014): 3183. http://dx.doi.org/10.1182/blood.v124.21.3183.3183.
Full textAbstract:
Abstract Background: Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), are chronic MPNs associated with a broad array of symptoms that may negatively impact patients’ quality of life (QoL). To enhance patient care, it is important to have a current and clear understanding of how MPNs affect the overall health and daily lives of patients. The MPN LANDMARK SURVEY was developed to examine patients’ perceptions of these MPNs related to disease burden, QoL, productivity, and activities of daily living (ADLs). Methods: Eligible patients diagnosed with an MPN were recruited to participate in an online survey conducted from May–July 2014in the US. Patients were asked about the overall burden of disease and impact of symptoms on their QoL, productivity, and ADLs. Descriptive analyses were conducted to assess these outcomes and examined by calculated (not reported) prognostic risk score (MF - DIPSS: Passamonti, Blood 2010; PV: Tefferi, Leuk 2013; ET - IPSET: Passamonti, Blood 2012) and symptom severity quartiles, which were determined using the MPN Symptom Assessment Form (MPN-SAF) total symptom scores. Results: 813 patients (MF=207; PV=380; ET=226) responded to the survey. A majority of patients were female (MF, 54%; PV, 62%; ET, 72%), approximately half were aged 60–74 years (MF, 55%; PV, 51%; ET, 46%), and most were covered by health insurance (>98%). Nearly half (48%) were diagnosed within the last 5 years and average time to diagnosis from first symptoms was >2 years. A high proportion of patients had intermediate to high prognostic risk scores (MF, 94%; PV, 87%; ET, 44%). The majority of patients reported feeling anxious or worried about their MPN (MF, 91%; PV, 78%; ET, 74%). Among all groups, fatigue was the most severe symptom reported (mean MPN-SAF score=6.0–6.4 on a scale of 0–10). A subset of patients in each group described their symptoms as very severe (severity score ≥7 on a scale of 0–10; MF: fatigue [59%], problems with sexual desire [49%], inactivity [46%]; PV: inactivity [48%], fatigue [49%], problems with sexual desire [49%]; and ET: problems with sexual desire [49%], fatigue [50%], headaches [40%]). The majority of patients reported that MPN-related symptoms reduced their QoL (MF, 81%; PV, 66%; ET, 57%); this was reported in all risk groups but more frequently by patients with a high risk score vs a low risk score in MF and ET (MF, 89% vs 69%; PV, 63% vs 65%; ET, 71% vs 59%). A more substantial QoL impact was reported by patients in high vs low symptom quartiles (MF, 95% vs 51%; PV, 94% vs 33%; ET, 93% vs 15%). Similarly, MPNs also had a marked negative impact on reduced work hours, sick days, voluntary job termination, receipt of medical disability, early retirement, and ADLs (Table 1). For example, among patients employed, approximately one fourth reported missing ≥1 day of work (MF, 29%; PV, 19%; ET, 23%) in the last 30 days before the survey. Even patients with low prognostic risk scores often reported missing ≥1 day of work (MF, 33%; PV, 23%; ET, 22%) or cancelling ≥1 day of planned activities (MF, 46%; PV, 35%; ET, 34%). Patients in the high vs low symptom quartiles were more likely to call in sick to work (MF, 48% vs 0%; PV, 52% vs 4%; ET, 38% vs 0%) or cancel ≥1 day of planned activities (MF, 77% vs 5%; PV, 56% vs 7%; ET, 67% vs 3%). Conclusion: The findings from this large, first-of-its-kind survey demonstrate a marked burden of disease across all 3 MPNs that is not limited to symptoms but extends to QoL, productivity, and ADLs. Although high prognostic risk scores have long been associated with a significant burden of disease, in this study, patients with a low risk score also reported significant burden. The symptom burden reported is consistent with previous studies, thus validating the present dataset. MPN treatment considerations should include reducing the symptom burden and improving QoL and productivity to enhance the overall health and lives of MPN patients. Disclosures Mesa: Incyte Corporation: Research Funding; CTI: Research Funding; Gilead: Research Funding; Genentech: Research Funding; Eli Lilly: Research Funding; Promedior: Research Funding; NS Pharma: Research Funding; Sanofi: Research Funding; Celgene: Research Funding. Miller:Incyte Corporation: Honoraria, Research Funding. Thyne:Incyte Corporation: Speakers Bureau. Mangan:Incyte Corporation: Membership on an entity's Board of Directors or advisory committees; Alexion Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Goldberger:Incyte Corporation: Membership on an entity's Board of Directors or advisory committees. Fazal:Incyte Corporation: Consultancy, Research Funding, Speakers Bureau; Gilead: Research Funding, Speakers Bureau. Ma:Incyte Corporation: Consultancy. Wilson:Incyte Corporation: Honoraria. Dubinski:Incyte Corporation: Employment, Equity Ownership. Boyle:ICF International: Employment, Equity Ownership. Mascarenhas:Incyte Corporation: Consultancy, Research Funding; Novartis Pharmaceuticals Corporation: Research Funding.
42
Michalicka, Tomas, Drahoslav Lancaric, and Hana Zach. "Adopting the Diversity Management Approach. Case of Slovakia." SHS Web of Conferences 92 (2021): 02042. http://dx.doi.org/10.1051/shsconf/20219202042.
Full textAbstract:
Research background: Towards the end of the previous century the issue of management of diversity in organisations gained a prominent place in both academic and societal debates. For any multicultural country, such as the United States or Great Britain, the issue of diversity is not new. However, diversity has not been as frequently researched in the countries of the Visegrad region: the Slovak Republic, the Czech Republic, Poland and Hungary. Purpose of the article: Using the data about 278 business organizations in Slovakia, we focus on the background of the implementation of diversity management from the point of view of factors having a direct influence on this process. We evaluate the influence of the legal form (as an expression of the number of owners and the ability to quickly adopt a new concept) of the business organisation, the size (number of employees) of the business organisation, the share of the foreign capital in the ownership structure of the organisations, the sector of economy the organization operates in, its performance and the existence of HR unit in the organizational structure. Methods: To evaluate the influence of the selected factors linear modelling was used. Findings & Value added: The study theoretically contributes to human resource management, talent management and organizational behaviour theories, and offers several policy implications for decision makers. Specifically, it deals with the relationship between the implementation of the diversity management selected organizations` characteristics.
43
Ingram, Lucy A., Mark Macauda, Carolyn Lauckner, and Alyssa Robillard. "Sexual Behaviors, Mobile Technology Use, and Sexting Among College Students in the American South." American Journal of Health Promotion 33, no. 1 (June 3, 2018): 87–96. http://dx.doi.org/10.1177/0890117118779008.
Full textAbstract:
Purpose: To examine sexual, mobile technology, and sexting behaviors of college students. Design: A cross-sectional study design was employed. Setting: Study sites were 2 universities in the southern United States. Subjects: Data were collected from 254 participants via online survey of college students. Measures: The survey included 268 items inclusive of measures from previously validated sources. Variables for this study included technology ownership/use, online/mobile dating site use, sexting behaviors/attitudes, and sexual behaviors. In particular, the Sexting Attitudes Scale has been previously validated with other researchers providing comparative data. Analysis: Chi-square and Mann-Whitney tests were used for group comparisons. Logistic regression analysis was used to examine predictors of sexting behavior. Results: Of the 254 participants, over 80% had ever had sex, and participants were more likely to use condoms with partners who they were not in a committed relationship compared to those to whom they were committed (χ2 = 27.324, P = .0001). Seventy percent had ever sexted, and sexting attitudes ranged from approximately 80% agreeing that sexting is “risky” or can leave one “vulnerable” compared to 43% agreeing that sexting is “fun.” Sexting was associated with having multiple sexual partners (odds ratio [OR] = 2.47, 95% confidence interval [CI]: 1.36-4.47) and sexually transmitted infection testing history (OR = 2.08, 95% CI: 1.03-4.18). Conclusion: Study findings should be considered as interventionists plan sexual health and risk prevention programs for college students.
44
Scharf, Adria L. "Case study: Central States Manufacturing, Inc." Journal of Participation and Employee Ownership 4, no. 2 (November 11, 2021): 190–93. http://dx.doi.org/10.1108/jpeo-09-2021-0012.
Full textAbstract:
PurposeThis case study examines employee share ownership at Central States Manufacturing, where the employee stock ownership plan (ESOP) shares stunning sums of wealth with employees. Central States designs its ESOP to allow participants to access a portion of their ownership wealth while they are still employed at the company, through hardship and in-service withdrawals. This may make the “wealth benefit” of employee ownership more meaningful to lower-wage workers navigating economic challenges. The case study adds to the discussion about how employee ownership can benefit low- and moderate-wage workers and close the wealth gap.Design/methodology/approachData were collected via: (1) published accounts, (2) structured qualitative interview with the chief financial officer (CFO), (3) follow-up emails and phone communication with company contact and (4) review of plan document language.FindingsWorkers at Central States Manufacturing – including truck drivers and production workers – build large sums of wealth through the ESOP. Central States innovates in its ESOP by permitting workers to access a portion of their ownership wealth while they are still working through hardship and service withdrawals.Research limitations/implicationsThis is a mini-case study heavily reliant on the information provided by the CFO, in combination with background publications, and plan document language. It does not include employee interviews.Originality/valueThis paper lifts up an innovative company whose success and innovative ESOP plan design benefit frontline workers.
45
Gladman, D. D., L. Coates, L. Gossec, J. Aelion, J. Vasandani, S. Cheng, L. Tang, S. Jardon, S. Richter, and P. J. Mease. "POS1080 CHARACTERIZATION OF JOINT DISTRIBUTION AND DISEASE BURDEN IN PATIENTS WITH EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS: RESULTS FROM THE ONGOING FOREMOST STUDY." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 865.2–866. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2467.
Full textAbstract:
BackgroundOligoarticular psoriatic arthritis (PsA) is commonly reported in early disease. Although fewer joints are involved, there may be significant impact on patients’ (pts) quality of life. The ongoing FOREMOST study (NCT03747939) is investigating the efficacy of apremilast vs placebo for treatment of early oligoarticular PsA (>1 but ≤4 tender and swollen joints involved).ObjectivesTo characterize disease burden in pts with early oligoarticular PsA and disease phenotype including location and size of involved joints and presence of certain baseline clinical PsA manifestations in FOREMOST pts.MethodsBaseline swollen and tender joint distribution was analyzed. Baseline disease burden was assessed in the overall group and a subgroup with small joint involvement only (for context) using clinical disease activity measures, pt-reported outcomes, and additional PsA manifestations.ResultsAt data cut-off for analysis, 220 pts of 285 planned were enrolled. In the overall group, disease duration was <1 year and joint distribution for swollen or tender joints involved predominantly small joints, with ~48% of joint involvement observed in finger proximal interphalangeal (PIP) joints and <2% in temporomandibular and clavicular joints across swollen or tender joints (Figure 1). Mean Physician’s and Patient Global Assessment of Disease Activity (PhGA and PtGA, respectively) scores were 43.9 and 51.3; mean pt pain assessment score was 50.7. Mean Health Assessment Questionnaire Disability Index (HAQ-DI) functional assessment score was 1.0; 25.5% of pts had HAQ-DI ≤0.5. Pts reported an average PsA Impact of Disease (PsAID-12) domain score of 4.7. Additional manifestations of PsA at baseline included dactylitis (14.5%), enthesitis (32.7%), nail involvement (67.3%), and skin disease (47.7% with body surface area [BSA] ≥3%). Within the overall group, 59% had >1 joint size involved (small [metacarpophalangeal, metatarsophalangeal, distal interphalangeal, PIP, hand carpometacarpal and mid-tarsal]; intermediate [wrist, elbow, ankle, temporomandibular, acromioclavicular, sternoclavicular]; large [shoulder, hip, knee]). Of those with only 1 joint size involved (41% of pts), the majority had small joint involvement predominantly in PIPs (n=84 for small joints; n=1 for intermediate joints; n=5 for large joints). The overall pattern of clinical and disease presentation indicated elevated burden for pts with early oligoarticular PsA, including those pts with only small joints involved (Table 1).Table 1.CharacteristicsOverall Population (PBO + APR), N=220Small Joints Only (PBO + APR), N=84Age, mean, y49.651.3Men, n (%)98 (44.5)40 (47.6)Europe/Russia, n (%)47 (21.4)/66 (30.0)22 (26.2)/11 (13.1)Canada/United States, n (%)8 (3.6)/99 (45.0)1 (1.2)/50 (59.5)Body mass index, mean, kg/m230.429.3Duration of disease, mean, y0.690.71Previous cDMARD use, n (%)143 (65.0)48 (57.0)Tender joint count (0–68), mean3.23.1Swollen joint count (0–66), mean2.62.8PhGA (VAS 0–100)a, mean43.939.0PtGA (VAS 0–100)a, mean51.345.6Patient’s Assessment of Pain (VAS 0–100)a, mean50.746.3Dactylitis present, n (%)32 (14.5)14 (16.7)Enthesitis present, n (%)72 (32.7)21 (25.0)BSA ≥3%, n (%)105 (47.7)34 (40.5)Nail involvement present, n (%)148 (67.3)53 (63.1)HAQ-DI (0–3)a, mean1.020.84HAQ-DI ≤0.5, n (%)56 (25.5)31 (36.9)PsAID-12 (0–10)a, mean4.733.98cDMARD, conventional disease-modifying antirheumatic drugs; VAS, visual analog scale.aHigher scores indicate greater burden/worse status. Early oligoarticular = ≤2 years in the initial protocol; ≤5 years in the current protocol for inclusion.Figure 1.FOREMOST population: baseline demographics and disease burden in the overall population and pts with involvement in small joints onlyConclusionIn FOREMOST, despite few joints involved, pts with early oligoarticular PsA experienced high disease burden and impaired quality of life. Small joint involvement, although less commonly expected in oligoarticular PsA, was the most frequently observed pattern.AcknowledgementsThe authors thank the patients, their families, and all investigators involved in this study. This study was funded by Amgen Inc. Writing support was funded by Amgen Inc. and provided by Kristin Carlin, BSPharm, MBA, of Peloton Advantage, LLC, an OPEN Health company, and Cathryn M. Carter, MS, employee of and stockholder in Amgen Inc.Disclosure of InterestsDafna D Gladman Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB – grant/research support or consulting fees, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB – grant/research support or consulting fees, Laura Coates Speakers bureau: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Moonlake, Novartis, Pfizer, and UCB –grant/research support, consulting fees, and/or speaker/honoraria, Consultant of: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Moonlake, Novartis, Pfizer, and UCB –grant/research support, consulting fees, and/or speaker/honoraria, Grant/research support from: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Moonlake, Novartis, Pfizer, and UCB –grant/research support, consulting fees, and/or speaker/honoraria, Laure Gossec Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Galapagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB, Grant/research support from: Amgen, Galapagos, Lilly, Pfizer, and Sandoz, Jacob Aelion Grant/research support from: AbbVie, Celgene, Eli Lilly and Regeneron – speakers bureau. AbbVie, Ardea Biosciences, AstraZeneca, Bristol Myers Squibb, Celgene, Centocor, Eli Lilly, Galapagos, Genentech, GlaxoSmithKline, Human Genome Sciences, Janssen, Merck, Mesoblast, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Takeda, UCB, and Vertex, Jitendra Vasandani: None declared, Sue Cheng Shareholder of: Stock ownership in Amgen Inc., Employee of: Employment by Amgen Inc., Lihua Tang Shareholder of: Stock ownership in Amgen Inc., Employee of: Employment by Amgen Inc., Shauna Jardon Shareholder of: Stock ownership in Amgen Inc., Employee of: Employment by Amgen Inc., Sven Richter Shareholder of: Stock ownership in Amgen at time of study, Employee of: Employment by Amgen at time of study., Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun, and UCB – grant/research support and consultant; Boehringer Ingelheim and GlaxoSmithKline – consultant, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun, and UCB
46
Wiefek, Nancy, Corey Rosen, and Timothy Garbinsky. "Promoting employee ownership: a look at the states." Journal of Participation and Employee Ownership 2, no. 3 (December 9, 2019): 183–89. http://dx.doi.org/10.1108/jpeo-09-2019-0024.
Full textAbstract:
Purpose Close to half of all privately held companies in the USA are owned by baby boomers, meaning 2.7m American businesses are owned by someone age 55 or older. In the coming decades, all of these businesses will either change owners or disappear. The median state has 34,000 businesses approaching an ownership transition. The effects of this generational shift will be felt in cities, small towns and rural areas. At the same time, state governments are struggling with the challenge of preserving jobs and stimulating local economies buffeted by larger economic trends. States currently spend an estimated $45bn to $70bn a year on efforts to attract and retain jobs. If even a fraction of these exiting owners pursued an Employee Stock Ownership Plan (ESOP) as their business exit strategy, the potential positive impact on workers, communities and state economies would be substantial. Yet, many business owners are not even aware of ESOPs as an option. In light of this knowledge gap, many of these businesses will instead shut down or sell to outside investors who may not be interested in preserving and growing local jobs. This paper aims to discuss these issues. Design/methodology/approach Review of state information and statistics on employee ownership. Findings Currently, there are around 6,660 ESOPs in the USA holding total assets of nearly $1.4 trillion. These plans cover 14.2m participants. The Midwest is home to the greatest number of ESOPs, followed by the South. There is a least one ESOP headquartered in 4,131 distinct zip codes. Practical implications In order to increase the effectiveness and penetration of local outreach and education, states can: create an office of employee ownership with a dedicated staff person. The office could exist within a state agency or as a nonprofit receiving state funding; provide grants to one or more nonprofits to run an outreach program; hold seminars statewide in conjunction with professional, business, and trade publications and organizations; publish and disseminate brochures and other material; and work with the media to encourage stories on local ESOP companies. In order to promote ESOPs as an attractive alternative to private equity, outside competitors, and other potential purchasers of the business, ESOP outreach should: focus on business owners who are approaching retirement or a liquidity event, as opposed to start-ups or businesses who are interested in progressive management. Focus on the human side and emotional impact of employee ownership. Videos and other personal testimonials contrasting the storylines of a company that becomes employee-owned vs one that becomes owned by an outside investor can be powerful. Take advantage of the ESOP community by facilitating peer-to-peer connections, where company leaders talk with their peers who have sold to an ESOP. These connections are usually fostered based on location or industry. Take care to ensure that the center is seen as providing objective information as opposed to being perceived as trying to “sell” owners on the idea. Originality/value This is the first published review of ESOPs in the states.
47
Khorana, Alok A., Frank Peacock, Sally G. Tamayo, Zhong Yuan, Nicholas Sicignano, Kathleen Hopf, and Manesh Patel. "Major Bleeding Events Among Cancer and Non-Cancer Patients Taking Rivaroxaban for Venous Thromboembolism Treatment in a Department of Defense Health System Cohort." Blood 128, no. 22 (December 2, 2016): 1447. http://dx.doi.org/10.1182/blood.v128.22.1447.1447.
Full textAbstract:
Abstract Background: Cancer patients are at increased risk of both venous thromboembolism (VTE) and bleeding, but real world bleeding rates with contemporary anticoagulants are not known. Purpose: To describe the incidence of major bleeding (MB) in VTE patients treated with rivaroxaban, and to compare differences in MB incidence and characteristics among patients with active cancer, history of cancer, and no current or past cancer. Methods: We queried over 10 million electronic medical records (EMRs) from the United States Department of Defense healthcare system from November 2, 2012 to September 30, 2015 to identify MB events in VTE patients treated with rivaroxaban. The Cunningham algorithm was used for identifying MB, and VTE was determined by diagnosis codes. Presence of cancer was assessed from 5 years prior to index rivaroxaban exposure through end of study, and categorized by active cancer, history of cancer, and no cancer. Active cancer was defined by one of the following: 1) a metastatic diagnosis code within 6 months prior to or overlapping with rivaroxaban exposure, 2) chemotherapy and/or radiation codes within 6 months prior to rivaroxaban exposure, 3) cancer-related surgery overlapping with rivaroxaban exposure, or 4) leukemia and/or indolent lymphoma codes at any point within the entire assessment window. History of cancer was defined as the presence of any cancer diagnosis within the 5-year baseline period not meeting the definition of active cancer. Patients with active cancer or history of cancer were further categorized by cancer site/type. Incidence, outcomes, demographics, and bleeding risk scores were evaluated by cancer status. A Cox proportional hazard model was used to assess the association between cancer status and rate of MB adjusting for baseline characteristics. Results: The study population comprised 9,638 VTE patients on rivaroxaban, including 1,728 (17.9%) with active cancer, 1,548 (16.1%) with history of cancer and 6,362 (66.0%) with no cancer. Of these, 130 (1.3%) experienced MB. After stratifying by cancer status, MB occurred at a rate of 2.61 (95% CI 1.80-3.78) per 100 person-years in those with active cancer, 3.18 (95% CI 2.17-4.67) per 100 person-years in those with history of cancer, and 2.25 (95% CI 1.80-2.81) per 100 person-years in those with no cancer. No significant difference in the incidence of MB was found between those with cancer (active or history) and those without cancer (HR 1.01; 95% CI 0.70-1.47, p-value 0.94) after adjusting for age, sex, and baseline comorbidities. Neither history of cancer nor active cancer when independently compared to no cancer was significantly associated with MB after multivariate adjustment. MB rates varied notably by cancer site. Additional key findings are presented in Table 1. Conclusion: In this large United States Department of Defense cohort study of rivaroxaban users treated for VTE, incidence of MB is relatively low and not significantly different between cancer and non-cancer patients. Fatal outcomes associated with bleeding hospitalization were also uncommon across all the cancer groups. These data should provide assurance to oncology providers regarding the safety of rivaroxaban use in the real-world setting. Disclosures Khorana: Pfizer: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Leo: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria; Bayer: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Halozyme: Consultancy, Honoraria; Janssen Scientific Affairs, LLC: Consultancy, Honoraria, Research Funding. Peacock:Phillips: Consultancy; Comprehensive Research Associates LLC: Equity Ownership; Pfizer: Research Funding; Banyan: Research Funding; Cardiorentis: Consultancy, Research Funding; Portola: Consultancy, Research Funding; Abbott: Research Funding; Emergencies in Medicine LLC: Equity Ownership; Ischemia Care: Consultancy; Janssen: Consultancy, Research Funding; Alere: Consultancy, Research Funding; Roche: Research Funding; The Medicine's Company: Consultancy, Research Funding; ZS Pharma: Consultancy, Research Funding; Prevencio: Consultancy. Yuan:Janssen Research and Development: Employment; Johnson & Johnson: Other: Mr. Yuan owns stocks in Johnson & Johnson.. Sicignano:Janssen Research and Development: Other: NMS is an employee of Health ResearchTx LLC, which has a business relationship with Janssen.. Hopf:Janssen Research and Development: Other: KPH is an independent contractor for Health ResearchTx LLC, which has a business relationship with Janssen . Patel:National Heart Lung and Blood Institute: Research Funding; Janssen: Consultancy; Bayer: Consultancy; Otsuka: Consultancy; Johnson & Johnson: Consultancy; AstraZeneca: Consultancy, Research Funding; Heart Flow Technologies: Research Funding; Agency for Healthcare Research and Quality: Research Funding.
48
Chatfield, Sheryl L., Rachael Nolan, Hannah Crawford, and Jeffrey S. Hallam. "Experiences of hand hygiene among acute care nurses: An interpretative phenomenological analysis." SAGE Open Medicine 4 (January 1, 2016): 205031211667509. http://dx.doi.org/10.1177/2050312116675098.
Full textAbstract:
Objective: Occurrences of healthcare-associated infections are associated with substantial direct and indirect costs. Improvement in hand hygiene among acute care nurses has potential to reduce incidence of healthcare-associated infections. Findings from reviews of intervention research have not conclusively identified components that are more or less efficient or effective. Much prior qualitative research has focused on descriptive analysis of policies and practices rather than providing interpretive explorations of how individuals’ perceptions of hygiene might drive practices. Methods: We conducted qualitative interview research with eight nurses in the United States who were employed in various patient-care roles. We analyzed the data using an interpretative phenomenological analysis methodology to explore how nurses described their perceptions of, and experiences with, hygiene. We developed themes that explored individual, workplace, and management influences on perception of hygiene. Results: Developed themes include practical hygiene, risky business, and hygiene on trial; the latter theme described the conflict between how nurses perceived their own hygiene practices and how they felt hospital management perceived these practices. Other findings included that participants distinguished between policy-mandated use of sanitizer and a personal sense of cleanliness; the latter was more likely to be associated with scrubbing or removal of contaminants than with use of protectants. Conclusion: While participants asserted support for facility hand hygiene policies, their behavior in certain instances might be mediated by broadly defined emergent situations and a belief that it is not currently possible to establish a causal link between an healthcare-associated infections and a specific individual or occurrence. Researchers and infection prevention practitioners might consider soliciting greater input from nurses in planning hand hygiene improvement interventions, to encourage ownership, and emphasizing detailed cases as training content to take advantage of individuals’ sensory responses to hygiene.
49
Altaf, Mohsin, Sany Sanuri Mohd Mokhtar, and Noor Hasmini Abd Ghani. "Employee critical psychological states as determinants of employee brand equity in banking: a multi-group analysis." Banks and Bank Systems 12, no. 3 (September 4, 2017): 61–73. http://dx.doi.org/10.21511/bbs.12(3).2017.05.
Full textAbstract:
The objective of the study is to investigate the moderating role of affective sentiments of brand psychological ownership of an employee in the relationship among the cognitive sentiments of employee brand understanding and employee brand equity of conventional and Islamic banks. Survey method was adopted to collect data from respondents from conventional and Islamic banks. Data were collected from 279 employees from the banking sector using two-stage probability sampling. Disproportionate stratified random sampling and simple random sampling were employed to collect responses. To analyze the data, multi-group analysis was applied using PLS-SEM technique through SmartPLS 3.0. Results demonstrated that congruence between brand image and individuals has a moderating effect on the relationship between brand confidence and employee brand equity in conventional banking. Responsibility to maintain brand image has a moderating effect on the relationship between brand knowledge and employee brand equity in conventional banking. In case of Islamic banking, only congruence between brand image and individuals exhibited a moderating role on the relationship between brand knowledge and employee brand equity. The importance of brand understanding of employees and psychological ownership of a brand has been widely discussed in branding literature. However, only a few studies investigated the relationship between dimensions of employee brand understanding and the employee brand psychological ownership with employee brand equity. The cognitive and affective sentiments of both exogenous latent constructs, their relationships, and the interaction effect of cognitive and affective sentiments were seldom discussed in branding literature. This study covers the in-depth view and investigation of brand understanding of employ¬ees and the affective and cognitive sentiments of brand psychological ownership with em¬ployee behavior toward a brand. This study also uncovers the moderating role of affective sentiments of brand psychological ownership on the relationship between cognitive senti¬ments of employee brand understanding and employee brand equity. This study will help researchers analyze the in-depth role of affective and cognitive sentiments on brand sup¬portive related behavior of employees.
50
Moore, David G. "Employee Attitude Surveys in the United States." Relations industrielles 11, no. 3 (February 19, 2014): 150–60. http://dx.doi.org/10.7202/1022620ar.
Full textAbstract:
Summary The Author first discusses generally the employee attitude survey, describing the techniques commonly used, evaluating the ordinary questionnaire technique with its many drawbacks and limitations; these, however, can be — and have been — gradually corrected with time, and one of them has been refined into an instrument called the SRA Employee Inventory. The rest of the article is spent describing and assessing the Inventory, and finally giving the results and trends in employee attitudes which it has yielded.